prompt,answer
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 165990.80 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-07-02 to 2023-07-09, AMGN's stock price decreased from 218.52 to 215.20. Company news during this period are listed below:

[Headline]: Insiders At Amgen Sold US$1.9m In Stock, Alluding To Potential Weakness
[Summary]: Many Amgen Inc. ( NASDAQ:AMGN ) insiders ditched their stock over the past year, which may be of interest to the...

[Headline]: 4 Big Pharma Stocks On Sale Right Now 
[Summary]: The key is to buy a basket of the cheap ones, so that gains in a few of them can offset disappointing performance in others.

[Headline]: Rose's Income Garden 80 Stock Portfolio: Update H1 2023 Green With 7 June Raises
[Summary]: Rose's Income Garden portfolio saw 39 companies pay dividends in June, with seven raises and one cut. Click here for a detailed analysis.

[Headline]: Amgen Inc. stock falls Friday, underperforms market
[Summary]: Shares of Amgen Inc. slid 1.94% to $218.65 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...

[Headline]: Buy 3 July Dogs Of The Dow, Watch 6
[Summary]: Analyst 1-year targets showed 10 highest-yield Dow stocks producing 1.62% LESS gain from $5k invested in the lowest-priced 5. Click for our exclusive stock lists.

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-07-09, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-07-09 to 2023-07-16) is up by 4-5%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen Inc. continues to be a key player in the biotechnology sector, known for its innovative approach and driving progress within the industry.
2. Despite insider selling, it is important to note that insiders selling stock does not always imply a negative outlook for the company, as insiders may have various reasons for selling including personal financial obligations or diversification.

[Potential Concerns]:
1. The recent underperformance of Amgen Inc. stock in a grim trading session for the overall stock market could be a cause for concern, as it indicates relative weakness compared to the market.
2. The lack of reported basic financials makes it difficult to assess the current financial health and performance of the company.

[Prediction & Analysis]:
Based on the available information, it is challenging to make an accurate prediction for the stock price movement of Amgen Inc. for the upcoming week. However, assuming a positive outlook, we predict a potential increase in the stock price by 4-5%.

While the recent underperformance of the stock and insider selling may raise concerns, it is important to consider the long-term track record and reputation of Amgen Inc. as a leading player in the biotechnology sector. The company's continued innovation and progress within the industry are positive factors that could positively impact the stock price in the upcoming week.

Additionally, the lack of reported basic financials makes it difficult to assess the current financial health and performance of the company. However, it is essential to consider other factors such as the overall market sentiment, potential upcoming news or developments within the biotechnology sector, and external market conditions while making investment decisions."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 165990.80 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-07-09 to 2023-07-16, AMGN's stock price increased from 215.20 to 223.84. Company news during this period are listed below:

[Headline]: These companies have beaten the Rule of 40 year after year
[Summary]: Morgan Stanley applied a VC filter to the stock market. Here's what it found.

[Headline]: Is There An Opportunity With Amgen Inc.'s (NASDAQ:AMGN) 45% Undervaluation?
[Summary]: Key Insights The projected fair value for Amgen is US$407 based on 2 Stage Free Cash Flow to Equity Amgen is estimated...

[Headline]: Amgen Inc. stock falls Tuesday, underperforms market
[Summary]: Shares of Amgen Inc. slipped 0.39% to $223.86 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...

[Headline]: Lucy Scientific Scores Richard Nanula as CEO After Senior Roles at Disney, Amgen, Starwood
[Summary]: By Daniella Parra Psychotropic industry innovator Lucy Scientific Discovery Inc. (Nasdaq: LSDI), has appointed Richard Nanula, former CFO at Amgen Inc. (Nasdaq: AMGN) and The Walt Disney Co. (NYSE: DIS), as its new CEO. With a career spanning senior executive positions at global giants like Starwood Hotels and Resorts, now part of Marriott International, Inc. […]

[Headline]: 2 Best Biotech Stocks to Buy Right Now
[Summary]: Many investors appreciate and rely on the regular cash flow that dividend stocks can generate for them.  Investors should seek out businesses with current products that can finance dividends, and future products that can sustain those dividends.  Here are two companies that could do just that, which income seeking investors should consider purchasing for their portfolios.

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-07-16, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-07-16 to 2023-07-23) is up by 3-4%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen Inc appointed Richard Nanula, a former CFO at Amgen Inc., as the new CEO of Lucy Scientific. This highlights the strong leadership and expertise within Amgen Inc, which could positively impact the company's reputation.
2. Amgen Inc was included in the list of companies that have beaten the Rule of 40 year after year, indicating the company's consistent performance and ability to generate value.

[Potential Concerns]:
1. Shares of Amgen Inc fell slightly during the analyzed period, underperforming the overall market. This could be a cause for concern as it raises questions about the company's competitiveness and ability to attract investors.
2. Amgen's stock was reported to be undervalued by 45%, which could indicate a potential lack of investor confidence in the company's future prospects.

[Prediction & Analysis]:
Based on the positive developments, such as the appointment of Richard Nanula as the new CEO of Lucy Scientific and the company's consistent performance, it is likely that Amgen Inc's stock price will experience an upward trend in the upcoming week. Additionally, the overall positive sentiment in the biotech sector further supports a positive outlook for Amgen Inc's stock.

However, the concerns regarding the underperformance of the stock and the perceived undervaluation could limit the potential upside. It is important to monitor the company's financial performance and investor sentiment in the coming week to make a more accurate prediction."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 165990.80 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-07-16 to 2023-07-23, AMGN's stock price increased from 223.84 to 231.12. Company news during this period are listed below:

[Headline]: Amgen Inc. stock rises Monday, still underperforms market
[Summary]: Shares of Amgen Inc. inched 0.18% higher to $227.84 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...

[Headline]: 3 Biotech Stocks for Getting Rich in 2023
[Summary]: The biotech industry is constantly evolving due to being on the cutting edge of the healthcare industry’s research and development. Large biotech companies such as Johnson and Johnson (NYSE:JNJ), Merck (NYSE:MRK), and AbbVie (NYSE:ABBV) offer investors steady and continual growth as well as decent dividends. But, a large portion of the industry involves much more volatile stocks. Many companies’ significant volatility in the biotech market attracts investors looking for a stock that will experie

[Headline]: Amgen Inc. stock rises Tuesday, outperforms market
[Summary]: Shares of Amgen Inc. rose 2.08% to $232.57 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...

[Headline]: Prediction: This Beaten-Down Stock Will Be a Biotech Giant by 2030
[Summary]: When you think of biotech giants, you may think of Amgen or Biogen. These companies have brought significant treatments to market over time -- and have generated billions of dollars in earnings, too. Most investors would be happy to find the next company set to follow in their footsteps.

[Headline]: 12 Highest Yielding Dow Jones Dividend Stocks
[Summary]: In this article, we discuss 12 highest yielding Dow Jones dividend stocks. You can skip our detailed analysis of dividend stocks and their performance in the past, and go directly to read 5 Highest Yielding Dow Jones Dividend Stocks. The Dow Jones Industrial Average, commonly referred to as the Dow, is one of the most […]

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-07-23, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-07-23 to 2023-07-30) is up by 0-1%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen Inc.'s stock price rose during the observed period, indicating positive market sentiment towards the company.
2. The company was mentioned in an article discussing biotech giants and their potential for future growth, positioning Amgen as a significant player in the industry.

[Potential Concerns]:
1. No specific financial information was reported, making it difficult to assess the company's current financial performance.
2. There was no major company-specific news that could provide a clear direction for the stock price movement.

[Prediction & Analysis]:
Given the limited information available, it is difficult to make a precise prediction for Amgen Inc.'s stock price movement for the upcoming week. However, considering the positive factors of the recent stock price rise and the company's recognition as a prominent player in the biotech industry, it is reasonable to expect a slight upward movement in the stock price. With that said, the prediction for next week is an increase of 0-1%.

It is important to note that future external factors, such as overall market conditions or specific company developments, may have a more significant impact on the stock price than the trends observed in the past week."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 165990.80 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-07-23 to 2023-07-30, AMGN's stock price increased from 231.12 to 232.64. Company news during this period are listed below:

[Headline]: Amgen Inc. stock falls Tuesday, underperforms market
[Summary]: Shares of Amgen Inc. slumped 0.05% to $235.31 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...

[Headline]: Building The Dividend Growth Portfolio In 2023
[Summary]: My US dividend growth portfolio, constructed in 2015, has outperformed the market by over 2% annually. Check out my dividend growth portfolio in 2023.

[Headline]: AbbVie (ABBV) Beats on Q2 Earnings & Sales, Raises '23 View
[Summary]: AbbVie's (ABBV) second-quarter 2023 earnings and sales beat estimates. The company raises its EPS guidance. Stock rises post the announcement.

[Headline]: Big Pharma's Balancing Act : Navigating Patent Thickets In The Age Of Biosimilars
[Summary]: The rise of biosimilars is transforming the pharmaceutical landscape, and Big Pharma is keenly aware that the fate of their blockbuster biologic drugs' exclusivity is at stake. These drugs, which...

[Headline]: With Hurricane Season Looming, Florida Faces an Insurance Meltdown 
[Summary]: Florida has long had hurricanes. But climate change is kicking in, the population of the state is growing, and private insurers are leaving the state. The...

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-07-30, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-07-30 to 2023-08-06) is up by 2-3%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen Inc. has established itself as a key player in the biotechnology sector, indicating a strong foundation and market presence.
2. The company has a history of dividend growth and outperforming the market, as mentioned in the news article.

[Potential Concerns]:
1. The recent news article stating that Amgen Inc. stock fell and underperformed the market could be a potential concern for investor sentiment.
2. The mention of biosimilars and patent challenges in the pharmaceutical industry could pose competition and pressure on Amgen's blockbuster biologic drugs.

[Prediction & Analysis]:
Based on the limited information available, it is difficult to make a precise prediction for Amgen Inc.'s stock price movement for the upcoming week. However, given the positive aspects of the company's strong market presence and history of dividend growth, along with the expectation of a 2-3% increase, it is possible that the stock price could continue to rise.

It is crucial to consider the potential concerns, such as the recent underperformance and the increasing competition in the pharmaceutical industry. These factors have the potential to impact investor sentiment and future performance.

Considering the overall positive developments and potential concerns, it is advisable for investors to closely monitor upcoming news and financials related to Amgen Inc., as they will provide a more comprehensive understanding of the company's performance and potential stock price movement."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 165990.80 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-07-09 to 2023-07-16, AMGN's stock price increased from 215.20 to 223.84. Company news during this period are listed below:

[Headline]: Is There An Opportunity With Amgen Inc.'s (NASDAQ:AMGN) 45% Undervaluation?
[Summary]: Key Insights The projected fair value for Amgen is US$407 based on 2 Stage Free Cash Flow to Equity Amgen is estimated...

[Headline]: Let's Check the Safety and Efficacy of Amgen's Charts Ahead of Earnings
[Summary]: AMGN's quarterly report is due in early August, so will buying the stock now pose any side effects?

[Headline]: The Blazing Weight-Loss Drug Battle: Can Anyone Unseat Undisputed Leaders Novo Nordisk And Lilly?
[Summary]: An overweight world is hungry for obesity treatments, driving big forecasts for weight loss drugs. For now, two pharmaceutical stocks own the market.

[Headline]: Is Amgen's Dividend Safe?
[Summary]: Despite multiple headwinds, the biotech's dividend appears to be a safe play for income investors.

[Headline]: ClearBridge Large Cap Value Strategy Q2 2023 Portfolio Manager Commentary
[Summary]: U.S. equities continued to make gains in Q2, driven by excitement over generative AI and improving market sentiment.

From 2023-07-16 to 2023-07-23, AMGN's stock price increased from 223.84 to 231.12. Company news during this period are listed below:

[Headline]: ClearBridge Large Cap Value ESG Strategy Q3 2023 Portfolio Manager Commentary
[Summary]: ClearBridge takes a fundamental-driven approach to proxies. Click here to read the full fund letter.

[Headline]: Amgen Inc. stock falls Wednesday, underperforms market
[Summary]: Shares of Amgen Inc. dropped 0.22% to $232.05 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...

[Headline]: Amgen Inc. (NASDAQ:AMGN) is largely controlled by institutional shareholders who own 77% of the company
[Summary]: Key Insights Institutions' substantial holdings in Amgen implies that they have significant influence over the...

[Headline]: Amgen Inc. stock underperforms Friday when compared to competitors despite daily gains
[Summary]: Shares of Amgen Inc. inched 0.68% higher to $234.82 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...

[Headline]: The 3 Most Undervalued Pharma Stocks to Buy Now: July 2023
[Summary]: Pharma stocks experienced an abysmal first half due to various factors. Rotation from defensive to cyclical sectors, drug price negotiations and upcoming patent cliffs have muddied the outlook. As a result, they have underperformed, creating undervalued pharma stocks to buy. Overall, the VanEck Pharmaceutical ETF (NASDAQ:PPH) is flat for the year. Only a few stocks have performed well. For instance, as of this writing, Eli Lilly (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) are up 23% and 16.67%, r

From 2023-07-23 to 2023-07-30, AMGN's stock price increased from 231.12 to 232.64. Company news during this period are listed below:

[Headline]: Amgen Inc. stock rises Monday, still underperforms market
[Summary]: Shares of Amgen Inc. inched 0.26% higher to $235.42 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...

[Headline]: Amgen (AMGN) Gains But Lags Market: What You Should Know
[Summary]: Amgen (AMGN) closed the most recent trading day at $235.42, moving +0.26% from the previous trading session.

[Headline]: Amgen Inc. stock underperforms Wednesday when compared to competitors
[Summary]: Shares of Amgen Inc. dropped 0.04% to $235.21 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...

[Headline]: AbbVie (ABBV) Beats on Q2 Earnings & Sales, Raises '23 View
[Summary]: AbbVie's (ABBV) second-quarter 2023 earnings and sales beat estimates. The company raises its EPS guidance. Stock rises post the announcement.

[Headline]: With Hurricane Season Looming, Florida Faces an Insurance Meltdown 
[Summary]: Florida has long had hurricanes. But climate change is kicking in, the population of the state is growing, and private insurers are leaving the state. The...

From 2023-07-30 to 2023-08-06, AMGN's stock price increased from 232.64 to 239.44. Company news during this period are listed below:

[Headline]: AMGEN ANNOUNCES 2023 THIRD QUARTER DIVIDEND
[Summary]: Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.13 per share dividend for the third quarter of 2023. The dividend will be paid on September 8, 2023, to all stockholders of record as of the close of business on August 18, 2023.

[Headline]: Amgen Insiders Sold US$1.9m Of Shares Suggesting Hesitancy
[Summary]: Over the past year, many Amgen Inc. ( NASDAQ:AMGN ) insiders sold a significant stake in the company which may have...

[Headline]: Amgen 2Q Profit Up as Revenue Rises 6%
[Summary]: By Brenda León 


  Amgen posted higher profit and revenue in the second quarter, helped by an increase in product sales across most therapeutic categories. 

  The Thousand Oaks, Calif.-based...

[Headline]: Amgen Inc. 2023 Q2 - Results - Earnings Call Presentation
[Summary]: The following slide deck was published by Amgen Inc.

[Headline]: US STOCKS-Wall St rises on Amazon boost; bond yields fall
[Summary]: Wall Street rose and bond yields fell on Friday after July jobs data showed a slowing in the U.S. labor market with wage gains, while Amazon's stellar earnings countered Apple's tepid sales forecast.  The yield on the 10-year benchmark note dipped on Friday after the jobs data, but still remained above 4%, partly boosting some megacap stocks.  ""At this point in some ways the jobs data doesn't do much to the Fed. The drama is now pivoting from the Fed to the Treasury,"" said David Russell, vice president of market intelligence at TradeStation.

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-08-06, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-08-06 to 2023-08-13) is up by more than 5%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen announced a $2.13 per share dividend for the third quarter of 2023, indicating the company's commitment to returning value to shareholders.
2. Amgen reported higher profit and revenue in the second quarter, driven by an increase in product sales across most therapeutic categories.
3. Despite multiple headwinds, Amgen's dividend appears to be a safe play for income investors, providing stability and attracting long-term investors.

[Potential Concerns]:
1. Amgen's stock underperformed the market in certain trading sessions, indicating potential market concerns or lack of investor confidence.
2. Some insiders at Amgen have sold a significant stake in the company, signaling hesitancy or uncertainty about the company's future performance.

[Prediction & Analysis]:
Based on the positive developments, such as the announcement of a dividend and strong financial performance in the second quarter, as well as the potential concerns surrounding insider selling and moments of underperformance, it is likely that Amgen's stock price will continue to increase in the upcoming week. The dividend declaration demonstrates the company's confidence in its financial position and ability to generate returns for shareholders. Additionally, the strong second-quarter results indicate the company's ability to navigate challenges and sustain growth. However, the concerns regarding insider selling and moments of underperformance should not be ignored and may introduce some volatility. Overall, considering the positive developments and the potential for further growth, it is expected that Amgen's stock price will increase by more than 5% in the upcoming week."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 165990.80 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-07-23 to 2023-07-30, AMGN's stock price increased from 231.12 to 232.64. Company news during this period are listed below:

[Headline]: Amgen: Huge Potential With Biosimilars And GLP-1
[Summary]: Amgen is now down nearly 20% since last November as money continues to rotate from defensive sectors into tech. Click here to read my latest analysis of AMGN stock.

[Headline]: Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
[Summary]: Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

[Headline]: Oppenheimer Reiterates AMGEN (AMGN) Outperform Recommendation
[Summary]: 

[Headline]: How AbbVie’s Humira Still Reigns, Despite New Competition
[Summary]: Revenue for blockbuster arthritis drug declined in the second quarter, largely due to discounts for middlemen.

[Headline]: Unveiling AbbVie's Hidden Risks: Cautionary Notes For Investors
[Summary]: AbbVie's Q2 2023 financial results exceeded expectations, driven by strong sales of innovative drugs Skyrizi and Rinvoq. Click here to read more.

From 2023-07-30 to 2023-08-06, AMGN's stock price increased from 232.64 to 239.44. Company news during this period are listed below:

[Headline]: Stock futures rise slightly as investors weigh Big Tech earnings, await key jobs data: Live updates
[Summary]: The three major indexes are on pace for week-to-date losses.

[Headline]: AMGEN REPORTS SECOND QUARTER FINANCIAL RESULTS
[Summary]: Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2023.

[Headline]: Amgen quarterly revenue rises 6%, profit beats Street estimates
[Summary]: (Reuters) -Amgen, which is facing U.S. Federal Trade Commission (FTC) delays to its planned acquisition of Horizon Therapeutics, on Thursday reported higher quarterly profit on strong sales of treatments for cholesterol, osteoporosis and other drugs.  The biotech company, which slightly raised its outlook for full-year revenue and profit, said it currently expects the Horizon deal to close by mid-December.  For the second quarter, Amgen reported revenue of $6.99 billion, up 6% from a year earlier, exceeding analysts' estimates of $6.68 billion, according to Refinitiv data.

[Headline]: Amgen (AMGN) Q2 Earnings Beat Estimates, 2023 View Raised
[Summary]: Amgen (AMGN) beats Q2 estimates for earnings and sales. It slightly raises its earnings and sales guidance for 2023.

[Headline]: Amgen's (NASDAQ:AMGN) Dividend Will Be Increased To $2.13
[Summary]: Amgen Inc. ( NASDAQ:AMGN ) will increase its dividend from last year's comparable payment on the 8th of September to...

From 2023-08-06 to 2023-08-13, AMGN's stock price increased from 239.44 to 258.37. Company news during this period are listed below:

[Headline]: Dow Jones Today: Index Rebounds with 400-Point Gain
[Summary]: Following last week’s downward turn, the Dow Jones Industrial Average bounced back, rising 407 points, or 1.2%, as investors readied for new inflation data to close out the week.

[Headline]: Want Rising Dividend Income? Buy Amgen Stock
[Summary]: Pharmaceutical company Amgen (NASDAQ: AMGN) is a favorite among income investors.  Here are four reasons that the stock could have a special place in a portfolio centered around dividend growth.  In the second quarter ended June 30, Amgen's total revenue increased by 5.9% year over year to $7 billion.

[Headline]: Amgen (NASDAQ:AMGN) jumps 13% this week, though earnings growth is still tracking behind five-year shareholder returns
[Summary]: When you buy and hold a stock for the long term, you definitely want it to provide a positive return. But more than...

[Headline]: Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
[Summary]: Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

[Headline]: How To Invest $100,000 Today: 5 Strategies Including The Near-Perfect Portfolio Strategy
[Summary]: Discover five investment strategies, including the Near-Perfect Portfolio, aimed at capital preservation, sustainable income, and long-term growth. Click for more.

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-08-13, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-08-13 to 2023-08-20) is up by 0-1%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen reported higher than expected revenue for the second quarter of 2023, driven by strong sales of treatments for cholesterol, osteoporosis, and other drugs.
2. Amgen beat earnings and sales estimates for the second quarter and raised its guidance for 2023.

[Potential Concerns]:
1. Amgen is facing U.S. Federal Trade Commission delays to its planned acquisition of Horizon Therapeutics, which may cause uncertainty and potential delays in future growth plans.

[Prediction & Analysis]:
Based on the positive developments of Amgen reporting strong financial results and beating expectations, it is likely that the stock price will continue to experience upward momentum. The company's ability to consistently deliver strong sales and exceed earnings estimates indicates a positive outlook for future growth. However, the potential concern around the acquisition delays could impact investor sentiment and introduce some volatility to the stock price. Overall, considering the positive factors, I would predict that Amgen's stock price will increase by 0-1% for the upcoming week."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 165990.80 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-07-23 to 2023-07-30, AMGN's stock price increased from 231.12 to 232.64. Company news during this period are listed below:

[Headline]: Bicara Therapeutics Expands Management Team with the Appointment of David Raben, M.D., as Chief Medical Officer
[Summary]: CAMBRIDGE - Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response, today announced the appointment of David...

[Headline]: Oppenheimer Reiterates AMGEN (AMGN) Outperform Recommendation
[Summary]: 

[Headline]: Amgen Inc. stock falls Tuesday, underperforms market
[Summary]: Shares of Amgen Inc. slumped 0.05% to $235.31 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...

[Headline]: How AbbVie’s Humira Still Reigns, Despite New Competition
[Summary]: Revenue for blockbuster arthritis drug declined in the second quarter, largely due to discounts for middlemen.

[Headline]: With Hurricane Season Looming, Florida Faces an Insurance Meltdown 
[Summary]: Florida has long had hurricanes. But climate change is kicking in, the population of the state is growing, and private insurers are leaving the state. The...

From 2023-07-30 to 2023-08-06, AMGN's stock price increased from 232.64 to 239.44. Company news during this period are listed below:

[Headline]: AMGEN REPORTS SECOND QUARTER FINANCIAL RESULTS
[Summary]: Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2023.

[Headline]: UPDATE 1-Amgen quarterly revenue rises 6%, profit beats Street estimates
[Summary]: Amgen, which is facing U.S. Federal Trade Commission (FTC) delays to its planned acquisition of Horizon Therapeutics, on Thursday reported higher quarterly profit on strong sales of treatments for cholesterol, osteoporosis and other drugs.  The biotech company, which slightly raised its outlook for full-year revenue and profit, said it currently expects the Horizon deal to close by mid-December.  For the second quarter, Amgen reported revenue of $6.99 billion, up 6% from a year earlier, exceeding analysts' estimates of $6.68 billion, according to Refinitiv data.

[Headline]: Amgen (AMGN) Q2 Earnings and Revenues Top Estimates
[Summary]: Amgen (AMGN) delivered earnings and revenue surprises of 12.61% and 5.41%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

[Headline]: RBC Capital Maintains AMGEN (AMGN) Sector Perform Recommendation
[Summary]: 

[Headline]: Amgen's (NASDAQ:AMGN) Dividend Will Be Increased To $2.13
[Summary]: Amgen Inc. ( NASDAQ:AMGN ) will increase its dividend from last year's comparable payment on the 8th of September to...

From 2023-08-06 to 2023-08-13, AMGN's stock price increased from 239.44 to 258.37. Company news during this period are listed below:

[Headline]: Amgen Gives You Growth, Dividend Growth, And Value
[Summary]: Amgen appears to remain undervalued for value and income investors. Read more to see a detailed analysis of AMGN stock.

[Headline]: CNBC Daily Open: Treasury bets
[Summary]: The U.S. economy has remained resilient and seemingly largely impervious to the Fed's highest rates in more than two decades.

[Headline]: Buy 2 August Dogs Of The Dow, Watch 5
[Summary]: Discover the criteria for stocks to be added to the Dow, the highest-yield stocks in August, and analyst predictions for stocks' performance. Read more here.

[Headline]: Amgen (NASDAQ:AMGN) Could Be A Buy For Its Upcoming Dividend
[Summary]: Amgen Inc. ( NASDAQ:AMGN ) is about to trade ex-dividend in the next four days. The ex-dividend date is one business...

[Headline]: Dividend Champion, Contender, And Challenger Highlights: Week Of August 13
[Summary]: A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read more to see the full August 13 weekly update.

From 2023-08-13 to 2023-08-20, AMGN's stock price increased from 258.37 to 259.78. Company news during this period are listed below:

[Headline]: Jefferies Maintains AMGEN (AMGN) Buy Recommendation
[Summary]: 

[Headline]: Improved Outlook For Horizon Therapeutics And Amgen
[Summary]: Horizon Therapeutics' better-than-expected Q2 eases concerns about Amgen acquisition failing to close due to Horizon's business underperformance. Read more here.

[Headline]: Horizon Therapeutics - Can Investors Profit From Amgen Deal Confusion?
[Summary]: Exploring the uncertain fate of the $28.5bn acquisition deal between Horizon Therapeutics and Amgen, and its potential impact on their share prices.

[Headline]: Amgen Stock Scores Relative Strength Rating Upgrade; Hits Key Benchmark
[Summary]: Amgen shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 68 to 80.

[Headline]: With 78% ownership of the shares, Amgen Inc. (NASDAQ:AMGN) is heavily dominated by institutional owners
[Summary]: Key Insights Given the large stake in the stock by institutions, Amgen's stock price might be vulnerable to their...

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-08-20, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-08-20 to 2023-08-27) is down by 2-3%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen reported strong Q2 financial results, with revenue of $6.99 billion, exceeding analysts' estimates, and a higher-than-expected profit.
2. The company raised its outlook for full-year revenue and profit, indicating confidence in its future performance.

[Potential Concerns]:
1. Amgen is facing delays in its planned acquisition of Horizon Therapeutics, with uncertainty surrounding the deal closure.
2. The stock underperformed the market during a trading session, indicating possible investor concerns.

[Prediction & Analysis]:
Considering the positive developments such as strong Q2 results and an improved outlook for revenue and profit, it appears that Amgen is on track for growth. However, the potential concerns surrounding the delayed acquisition and the stock's underperformance suggest some level of uncertainty in the market. 

Given this analysis, coupled with the general market conditions, it is reasonable to predict that Amgen's stock price may experience a slight downturn in the upcoming week, potentially decreasing by around 2-3%. This prediction takes into account both the positive developments and potential concerns mentioned above, as well as the overall market sentiment."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 165990.80 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-08-13 to 2023-08-20, AMGN's stock price increased from 258.37 to 259.78. Company news during this period are listed below:

[Headline]: Dividend Champion, Contender, And Challenger Highlights: Week Of August 13
[Summary]: A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read more to see the full August 13 weekly update.

[Headline]: Tracking George Soros's Portfolio - Q2 2023 Update
[Summary]: George Soros's 13F portfolio value decreased slightly from $6.49B to $6.41B, with 172 positions. Click here to read the portfolio's Q2 2023 update.

[Headline]: Could Amgen Stock Help You Become a Millionaire?
[Summary]: Healthcare company Amgen (NASDAQ: AMGN) has been a reliable investment to own over what has been a turbulent year for the broader market.  A particularly promising drug involved in the deal is Tepezza, a treatment for thyroid eye disease which could bring in up to $4 billion in peak annual sales.

[Headline]: Improved Outlook For Horizon Therapeutics And Amgen
[Summary]: Horizon Therapeutics' better-than-expected Q2 eases concerns about Amgen acquisition failing to close due to Horizon's business underperformance. Read more here.

[Headline]: Horizon Therapeutics - Can Investors Profit From Amgen Deal Confusion?
[Summary]: Exploring the uncertain fate of the $28.5bn acquisition deal between Horizon Therapeutics and Amgen, and its potential impact on their share prices.

From 2023-08-20 to 2023-08-27, AMGN's stock price decreased from 259.78 to 254.38. Company news during this period are listed below:

[Headline]: Bristol-Myers Squibb: Top Defensive Pick During Recessions With A Value Proposition
[Summary]: Discover why Bristol-Myers is a strong investment, undervalued with a promising dividend yield. After a slow start, expect a bullish turnaround.

[Headline]: Stock buybacks spur wealth inequality and stifle innovation. Should they be banned?
[Summary]: Stock buybacks have become a major source of wealth inequality and have stifled innovation in the U.S., according to this academic.

[Headline]: Amgen Inc. stock falls Friday, underperforms market
[Summary]: Shares of Amgen Inc. slid 0.09% to $256.38 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...

[Headline]: Amgen Presents Phase 2 OLPASIRan Data at ESC 2023
[Summary]: Amgen announced data from the final analysis of the Phase 2 OCEAN-DOSE study of olpasiran, a small interfering RNA during the Late-Breaking Science Session at the European Society of Cardiology ...

[Headline]: FTC Pauses Challenge to Amgen’s $27.8 Billion Deal for Horizon Therapeutics
[Summary]: The move gives the agency time to weigh a settlement that would allow the deal to close with conditions.

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-08-27, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-08-27 to 2023-09-03) is up by 0-1%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen's drug Tepezza, which treats thyroid eye disease, has the potential to bring in significant sales, estimated up to $4 billion annually.
2. Horizon Therapeutics' better-than-expected Q2 performance eases concerns about the acquisition deal with Amgen falling through, indicating a positive outlook for the collaboration.

[Potential Concerns]:
1. The decrease in Amgen's stock price during the period may be a cause for concern.
2. The uncertainty surrounding the fate of the acquisition deal between Amgen and Horizon Therapeutics may impact the share prices of both companies.

[Prediction & Analysis]:
Based on the positive developments and potential concerns, as well as the recent decrease in Amgen's stock price, we can predict that the company's stock price may remain relatively steady or register a slight increase of up to 1% during the upcoming week. The positive potential of Amgen's drug Tepezza, coupled with the successful Q2 performance of Horizon Therapeutics, provides a favorable outlook for Amgen's future collaborations and revenue generation. Furthermore, the recent news of the Federal Trade Commission pausing the challenge to Amgen's acquisition deal with Horizon Therapeutics suggests that the deal may still proceed, which could bode well for Amgen's stock performance. However, the overall uncertainty in the market, as indicated by the decrease in Amgen's stock price, could limit significant upward movement."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 165990.80 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-08-27 to 2023-09-03, AMGN's stock price increased from 254.38 to 254.71. Company news during this period are listed below:

[Headline]: August MDA Breakout Stocks Week 35 - 2023: High-Frequency Gainers To Give You An Edge
[Summary]: Two new sample Breakout Stocks for Week 35 curated by the MDA model for a 10% short-term upside along with a Dow pick. Click here for a detailed analysis.

[Headline]: Horizon (HZNP) Up as FTC Pauses Acquisition by Amgen Lawsuit
[Summary]: The Federal Trade Commission suspends its ongoing lawsuit to block Horizon's (HZNP) acquisition by Amgen until Sep 18, 2023. The company's stock rises 5.8% in response.

[Headline]: Biden admin unveils ten drugs picked for Medicare price negotiations
[Summary]: The Biden administration has released the list of the first ten drugs that will be subject to Medicare price negotiations. The Center for Medicare Director Dr. Meena Seshamani tells Yahoo Finance Live that they are looking at ""the benefits that a drug brings to populations. Does it address an unmet need? Does it address different populations that have needs?"" When it comes to why some drugs were chosen Dr. Seshamani says the organization followed the criteria written in the Inflation Reduction Act, adding that the list will not change. These are the ten drugs Medicare will be negotiating the prices of:Eliquis- Bristol-Myers Squibb (BMY), Pfizer (PFE) Jardiance- Boehringer Ingelheim, Eli Lilly (LLY) Xarelto- Bayer (BAYRY), Johnson & Johnson (JNJ) Januvia- Merck (MRK) Farxiga- AstraZeneca (AZN) Entresto- Novartis (NVS) Enbrel- Amgen (AMGN) Imbruvica- Johnson & Johnson (JNJ), AbbVie (ABBV) Stelara- Johnson & Johnson (JNJ) Fiasp, NovoLog- Novo Nordisk (NVO)

[Headline]: Amgen gets US FTC's go-ahead for $27.8 billion Horizon deal
[Summary]: The U.S. Federal Trade Commission (FTC) has allowed Amgen to continue its $27.8 billion acquisition of Horizon Therapeutics, while preventing the drugmaker from using anticompetitive tactics to extend the market dominance of two Horizon drugs.  The agreement, announced on Friday, ends months of uncertainty over the deal since the FTC in May filed a lawsuit over concerns that Amgen would leverage its drugs to secure favorable insurance coverage terms for Horizon's thyroid eye disease treatment Tepezza and gout drug Krystexxa.  Under the FTC settlement, Amgen is prohibited from bundling any of its products with Tepezza or Krystexxa, and from using any product rebate or contract term to exclude or disadvantage products that would compete with those drugs.

[Headline]: Amgen’s $27.8 Billion Horizon Takeover Allowed in FTC Accord
[Summary]: (Bloomberg) -- Amgen Inc. can move forward with its $27.8 billion takeover of Horizon Therapeutics Plc after the US Federal Trade Commission said Friday that it accepted a binding settlement that the combined company won’t bundle together two of Horizon’s blockbuster drugs.Most Read from BloombergHuawei Teardown Shows Chip Breakthrough in Blow to US SanctionsMercedes Bets on Range Boost in Swipe at Tesla’s EV LeadWhy China Is Avoiding Using ‘Bazooka’ to Spur EconomyDiamond Prices Are in Free Fal

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-09-03, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-09-03 to 2023-09-10) is up by 1-2%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. The FTC has allowed Amgen to proceed with its $27.8 billion acquisition of Horizon Therapeutics, providing a boost to Amgen's growth prospects and expanding its drug portfolio.
2. The suspension of the FTC lawsuit to block the acquisition of Horizon by Amgen has resulted in a 5.8% increase in the company's stock price, indicating positive investor sentiment.

[Potential Concerns]:
1. The Biden administration's release of the list of drugs subject to Medicare price negotiations includes Amgen's drug Enbrel. This could potentially lead to lower pricing and impact Amgen's revenue.
2. The ban on bundling Amgen's products with Tepezza or Krystexxa, as part of the FTC settlement, may put limitations on Amgen's marketing and pricing strategies.

[Prediction & Analysis]:
Considering the positive developments surrounding Amgen, such as the FTC allowing the Horizon acquisition and the resulting increase in stock price, it is likely that the company's stock will continue to exhibit positive momentum in the upcoming week. However, the potential concern regarding Medicare price negotiations and limitations imposed by the FTC settlement might limit the extent of the stock price growth. Therefore, my prediction would be for a moderate increase of 1-2% in Amgen's stock price for the next week. Investors should monitor any developments related to the Medicare price negotiations and the FTC settlement to assess their potential impact on Amgen's future prospects."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 165990.80 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-08-27 to 2023-09-03, AMGN's stock price increased from 254.38 to 254.71. Company news during this period are listed below:

[Headline]: Merck, Amgen, AbbVie products among first 10 drugs selected for Medicare price negotiations
[Summary]: Medicare on Tuesday announced the first 10 drugs selected for price negotiations, launching a historic and highly contentious process with big implications...

[Headline]: Biden admin unveils ten drugs picked for Medicare price negotiations
[Summary]: The Biden administration has released the list of the first ten drugs that will be subject to Medicare price negotiations. The Center for Medicare Director Dr. Meena Seshamani tells Yahoo Finance Live that they are looking at ""the benefits that a drug brings to populations. Does it address an unmet need? Does it address different populations that have needs?"" When it comes to why some drugs were chosen Dr. Seshamani says the organization followed the criteria written in the Inflation Reduction Act, adding that the list will not change. These are the ten drugs Medicare will be negotiating the prices of:Eliquis- Bristol-Myers Squibb (BMY), Pfizer (PFE) Jardiance- Boehringer Ingelheim, Eli Lilly (LLY) Xarelto- Bayer (BAYRY), Johnson & Johnson (JNJ) Januvia- Merck (MRK) Farxiga- AstraZeneca (AZN) Entresto- Novartis (NVS) Enbrel- Amgen (AMGN) Imbruvica- Johnson & Johnson (JNJ), AbbVie (ABBV) Stelara- Johnson & Johnson (JNJ) Fiasp, NovoLog- Novo Nordisk (NVO)

[Headline]: Medicare price negotiation list: What it means for pharma companies
[Summary]: On Tuesday, the Biden administration listed ten drugs subject to Medicare price negotiations. Yahoo Finance Health Care Reporter Anjalee Khemlani breaks down the list and how this may impact the pharmaceutical companies who profit from these drugs.   The ten drugs and pharma companies impacted are:  Eliquis - Bristol-Myers Squibb (BMY), Pfizer (PFE) Jardiance - Boehringer Ingelheim, Eli Lilly (LLY) Xarelto- Bayer (BAYRY), Johnson & Johnson (JNJ) Januvia - Merck (MRK) Farxiga - AstraZeneca (AZN) Entresto - Novartis (NVS) Enbrel - Amgen (AMGN) Imbruvica - Johnson & Johnson (JNJ), AbbVie (ABBV) Stelara - Johnson & Johnson (JNJ) Fiasp, NovoLog - Novo Nordisk (NVO)

[Headline]: Amgen Inc. stock falls Wednesday, underperforms market
[Summary]: Shares of Amgen Inc. sank 0.68% to $257.88 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...

[Headline]: Amgen resolves US regulator’s challenge to $28bn Horizon deal
[Summary]: Federal Trade Commission said it secured concessions from pharma company to resolve its competition concerns

From 2023-09-03 to 2023-09-10, AMGN's stock price increased from 254.71 to 257.41. Company news during this period are listed below:

[Headline]: AMGEN AND HORIZON THERAPEUTICS PLC RESOLVE FTC LAWSUIT, CLEARING PATH TO CLOSE ACQUISITION
[Summary]: THOUSAND OAKS - Amgen and Horizon Therapeutics plc today announced the entry into a consent order agreement with the Federal Trade Commission that resolves the pending FTC administrative...

[Headline]: Biden FTC’s Antitrust Bark Proves Worse Than Its Bite
[Summary]: Federal Trade Commission Chair  Lina Khan  has been open about her willingness to take on hard cases and lose.  “I’m certainly not someone who thinks success is marked by a 100% court record,” Khan has said.  Frequent defeats, including last week’s settlement with  Amgen  are weakening the agency’s hand, though.

[Headline]: High Times Ties Up with Lucy Scientific in Going-Public Transaction on Nasdaq
[Summary]: -High Times Holdings Corp. to exchange core IP assets for 19.9% stake in Lucy Scientific Discovery (NASDAQ: LSDI) plus milestone payments -Transaction creates liquidity opportunity for High Times shareholders who […]

[Headline]: Healthcare Stocks Push the Dow Higher
[Summary]: Healthcare stocks were gaining Thursday, helping to raise the Dow, while the Nasdaq and S&P 500 dropped. Shares of Amgen (ticker: AMGN) gained 1.7% as the biotechnology stock was the second-best performer in the Dow Jones Industrial Average.

[Headline]: Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know
[Summary]: In the latest trading session, Amgen (AMGN) closed at $259.43, marking a +1.98% move from the previous day.

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-09-10, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-09-10 to 2023-09-17) is up by 0-1%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen's resolution of the regulatory challenge to its $28 billion Horizon deal indicates a positive outcome for the company, allowing them to proceed with the acquisition and potentially expand their portfolio.
2. Amgen's stock price outpaced the market during the previous week, gaining 1.98% and being the second-best performer in the Dow Jones Industrial Average.

[Potential Concerns]:
1. The inclusion of Amgen's drug, Enbrel, in the list of drugs subject to Medicare price negotiations may result in potential pricing pressures and impact the company's profitability.
2. The FTC settlement with Amgen weakens the agency's hand and may signal increased scrutiny and potential regulatory challenges for the company in the future.

[Prediction & Analysis]:
Based on the positive developments and potential concerns, along with the recent stock performance, it is likely that Amgen's stock price will continue to show moderate upward movement in the upcoming week. The resolution of the regulatory challenge and the company's strong performance in the market indicate positive sentiment and potential growth opportunities. However, the inclusion of Enbrel in the list for Medicare price negotiations could add some pressure to the stock price. Considering these factors, a prediction of a slight increase of 0-1% in Amgen's stock price for the next week seems reasonable."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 165990.80 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-08-27 to 2023-09-03, AMGN's stock price increased from 254.38 to 254.71. Company news during this period are listed below:

[Headline]: August MDA Breakout Stocks Week 35 - 2023: High-Frequency Gainers To Give You An Edge
[Summary]: Two new sample Breakout Stocks for Week 35 curated by the MDA model for a 10% short-term upside along with a Dow pick. Click here for a detailed analysis.

[Headline]: Horizon (HZNP) Up as FTC Pauses Acquisition by Amgen Lawsuit
[Summary]: The Federal Trade Commission suspends its ongoing lawsuit to block Horizon's (HZNP) acquisition by Amgen until Sep 18, 2023. The company's stock rises 5.8% in response.

[Headline]: Best Buy results, Medicare negotiations list, Hurricane Idalia: Top stories
[Summary]: Best Buy (BBY) lowers its full-year sales outlook despite topping earnings estimates. The Biden administration has shared its list of ten prescription drugs that will be subject to pricing negotiations between manufacturers and Medicare. Tropical Storm Idalia has officially been upgraded to a hurricane. It's expected to make landfall on Florida's west coast on Wednesday.Yahoo Finance Live's Brad Smith highlights three of this morning's biggest stories.

[Headline]: Amgen’s $27.8 Billion Horizon Takeover Allowed in FTC Accord
[Summary]: (Bloomberg) -- Amgen Inc. can move forward with its $27.8 billion takeover of Horizon Therapeutics Plc after the US Federal Trade Commission said Friday that it accepted a binding settlement that the combined company won’t bundle together two of Horizon’s blockbuster drugs.Most Read from BloombergHuawei Teardown Shows Chip Breakthrough in Blow to US SanctionsMercedes Bets on Range Boost in Swipe at Tesla’s EV LeadWhy China Is Avoiding Using ‘Bazooka’ to Spur EconomyDiamond Prices Are in Free Fal

[Headline]: Dow Jones Today: Index Moves Up on Jobs Report
[Summary]: The Dow Jones finished higher by about 115 points, or 0.3%, on investors optimism that the latest employment report will help prompt the Fed to end its interest rate hikes.

From 2023-09-03 to 2023-09-10, AMGN's stock price increased from 254.71 to 257.41. Company news during this period are listed below:

[Headline]: Biden FTC’s Antitrust Bark Proves Worse Than Its Bite
[Summary]: Federal Trade Commission Chair  Lina Khan  has been open about her willingness to take on hard cases and lose.  “I’m certainly not someone who thinks success is marked by a 100% court record,” Khan has said.  Frequent defeats, including last week’s settlement with  Amgen  are weakening the agency’s hand, though.

[Headline]: Is Amgen A Worthy Investment Despite President Biden's Inflation Reduction Act?
[Summary]: Amgen discovers, develops, manufactures, and delivers human therapeutics worldwide. Find out why we initiate our coverage of AMGN stock with a hold rating.

[Headline]: Amgen Inc. (AMGN) Wells Fargo Securities Healthcare Conference (Transcript)
[Summary]: Amgen Inc. (NASDAQ:NASDAQ:AMGN) Wells Fargo Securities Healthcare Conference September 6, 2023 9:30 AM ETCompany ParticipantsArvind Sood - VP of IRPeter Griffith - EVP and CFOConference...

[Headline]: Amgen: Not An Investment Mistake, But It Was Better Before
[Summary]: Amgen's solid quarterly results and potential as a good investment are overshadowed by concerns over the Horizon acquisition and high debt levels. Learn more on AMGN stock here.

[Headline]: Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know
[Summary]: In the latest trading session, Amgen (AMGN) closed at $259.43, marking a +1.98% move from the previous day.

From 2023-09-10 to 2023-09-17, AMGN's stock price increased from 257.41 to 258.69. Company news during this period are listed below:

[Headline]: AMGEN PRESENTS NEW LUMAKRAS PLUS CHEMOTHERAPY DATA IN FIRST-LINE KRAS G12C NSCLC AT WCLC
[Summary]: THOUSAND OAKS - Amgen today announced exciting data from a study arm of the CodeBreaK 101 clinical trial, a Phase 1b study evaluating LUMAKRAS with carboplatin and pemetrexed in adult patients with...

[Headline]: AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
[Summary]: Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 11:40 a.m. BST on Thursday, Sept. 14, 2023. Peter H. Griffith, executive vice president and chief financial officer at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

[Headline]: BBH: Our Favorite Biotech ETF Can Keep Outperforming
[Summary]: VanEck Biotech ETF outperforms other industry ETFs due to its focus on large-cap leaders and the potential of AI in R&D programs. Read more on BBH ETF here.

[Headline]: 2 Top Dividend Stocks to Buy in September
[Summary]: If you're looking for dividend stocks that can provide steady income and growth potential, you might want to consider adding Amgen (NASDAQ: AMGN) and American Express (NYSE: AXP) to your portfolio.  Read on to find out more about these top-shelf dividend stocks.  Amgen is one of biotech's original pioneers, with a diversified portfolio of drugs and biosimilars that treat various diseases, such as cancer, cardiovascular, inflammation, and bone health.

[Headline]: Should You Consider Selling Amgen (AMGN)?
[Summary]: ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Value Strategy” second quarter 2023 investor letter. A copy of the same can be downloaded here. The strategy outperformed its Russell 1000 Value Index benchmark in the second quarter. The strategy benefited from nine of the 11 sectors in which it was invested for […]

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-09-17, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-09-17 to 2023-09-24) is up by 2-3%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. The suspension of the FTC lawsuit blocking Amgen's acquisition of Horizon Therapeutics allows the company to proceed with the $27.8 billion takeover. This move expands Amgen's product portfolio and potential revenue streams.
2. Amgen presented new data from a Phase 1b study evaluating LUMAKRAS in adult patients with KRAS G12C NSCLC. This positive data indicates potential for the drug in treating lung cancer.

[Potential Concerns]:
1. The Biden administration's list of prescription drugs subject to pricing negotiations with Medicare could impact Amgen's drug pricing and revenue.
2. Concerns over the high debt levels resulting from the Horizon acquisition may affect Amgen's financial stability.

[Prediction & Analysis]:
Based on the positive developments and potential concerns, I predict that Amgen's stock price will increase by 2-3% in the upcoming week. The positive development of the Horizon acquisition allows for potential growth in Amgen's product portfolio and revenue. Additionally, the positive data from the Phase 1b study further supports the company's growth potential. However, the concerns surrounding drug pricing negotiations with Medicare and the high debt levels resulting from the acquisition could impact investor sentiment. Therefore, while there are potential concerns, the overall positive developments outweigh them, leading to a predicted increase in the stock price."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 165990.80 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-09-17 to 2023-09-24, AMGN's stock price increased from 258.69 to 265.61. Company news during this period are listed below:

[Headline]: SCHD: Stop The Madness
[Summary]: Schwab U.S. Dividend Equity ETF offers a combination of slow growth blue chip names with consistent dividend hikes. Click here for a detailed analysis on SCHD.

[Headline]: FTC chair targets deals that have fallen in agency's 'blind spots'
[Summary]: FTC chair Lina Khan has her sights focused on challenging mergers & acquisitions in the healthcare and tech sectors, specifically those valued under $100 million. Khan argues that these mergers can snowball into larger monopolies when left unchecked. Senior Reporter for Yahoo Finance Anjalee Khemlani joins to breakdown Lina Khan's recent statement at the Oliver Wyman Health Innovation Summit in Chicago.

[Headline]: Nicholas Ward's Dividend Growth Portfolio: September 2023 Fair Value Update
[Summary]: I've been building my cash position in preparation for a market crash and taking advantage of high interest rates. Read more here.

[Headline]: 2 Dividend Growth Stocks to Buy Right Now
[Summary]: Dividends are great. They're a reliable source of passive income for retirees (and others) or can help boost long-term returns for investors who choose to reinvest them. But what happens when a company decreases or suspends its payouts? No investor wants to run into this problem.

[Headline]: The Hedge Fund That Made a Killing Betting Against Lina Khan
[Summary]: The efforts by Federal Trade Commission Chair Lina Khan to protect Main Street are inadvertently enriching some on Wall Street, generating outsize profits for Pentwater Capital Management and other large hedge funds that bet on merger deals.  In both cases, the FTC’s intervention spooked investors and sent shares of the target companies swinging.

Some recent basic financials of AMGN, reported at 2023-09-30, are presented below:

[Basic Financials]:

assetTurnoverTTM: 0.3207
bookValue: 7656
cashRatio: 2.0491329479768785
currentRatio: 2.8593
ebitPerShare: 3.8848
eps: 3.2156
ev: 168202.84
fcfMargin: 0.3639
fcfPerShareTTM: 17.5308
grossMargin: 0.7385
inventoryTurnoverTTM: 1.4407
longtermDebtTotalAsset: 0.6521
longtermDebtTotalCapital: 0.8667
longtermDebtTotalEquity: 7.7116
netDebtToTotalCapital: 0.3776
netDebtToTotalEquity: 3.3604
netMargin: 0.2506
operatingMargin: 0.3028
payoutRatioTTM: 0.589
pb: 18.6097
peTTM: 18.8311
pfcfTTM: 15.1909
pretaxMargin: 0.2821
psTTM: 5.3097
quickRatio: 2.5629
receivablesTurnoverTTM: 4.6784
roaTTM: 0.0904
roeTTM: 1.2908
roicTTM: 0.123
rotcTTM: 0.147
salesPerShare: 12.8309
sgaToSale: 0.2615
totalDebtToEquity: 7.8981
totalDebtToTotalAsset: 0.6679
totalDebtToTotalCapital: 0.8876
totalRatio: 1.0924

Based on all the information before 2023-09-24, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-09-24 to 2023-10-01) is up by 0-1%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen Inc's stock price showed a consistent upward trend during the past week, indicating positive investor sentiment.
2. The company's financials show strong indicators of profitability and efficiency, with high asset turnover, gross margin, and operating margin.

[Potential Concerns]:
1. The FTC chair's focus on challenging mergers and acquisitions in the healthcare sector could potentially affect the company's growth plans and limit its expansion opportunities.
2. The investigation by the FTC and potential scrutiny on merger deals may create uncertainty in the market and impact investor confidence in the short term.

[Prediction & Analysis]:
Based on the positive developments and potential concerns for Amgen Inc, I predict that the company's stock price will continue to show a slight upward movement in the upcoming week, with a potential increase of 0-1%. The consistent upward trend in the stock price, along with strong financial indicators, suggests that investors have confidence in the company's performance. However, the potential concerns surrounding FTC's focus on mergers and acquisitions in the healthcare sector might create some volatility in the short term. Overall, the positive momentum and strong financials should outweigh the concerns and support a modest increase in the stock price."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 165990.80 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-09-24 to 2023-10-01, AMGN's stock price increased from 265.61 to 266.66. Company news during this period are listed below:

[Headline]: The Hedge Fund That Made a Killing Betting Against Lina Khan
[Summary]: The efforts by Federal Trade Commission Chair Lina Khan to protect Main Street are inadvertently enriching some on Wall Street, generating outsize profits for Pentwater Capital Management and other large hedge funds that bet on merger deals.  In both cases, the FTC’s intervention spooked investors and sent shares of the target companies swinging.

[Headline]: Amgen discloses more than $400 million stake in recent IPO Neumora Therapeutics
[Summary]: An Amgen disclosure of a large stake in Neumora Therapeutics indicated the value of its investment in the biotech, which recently went public, has tripled.

[Headline]: Amgen Could Get a Piece of the Obesity Market
[Summary]: Amgen has a couple of shots on goal to break into one of the biggest markets the pharmaceutical industry has ever seen.

[Headline]: 3 Biotech Stocks to Watch Ahead of Potential Obesity Drug Approvals
[Summary]: The companies that already have obesity drugs can’t keep up with the demand for their treatments, and the demand for the drugs is only likely to become more intense. That’s because over 42% of the U.S. population was obese as of 2020, while the pervasive publicity around these drugs will make them more popular, and the social and political pressure for insurers to cover the treatments will become more intense. This has led to the rise of biotech stocks to buy. More specifically on the last point

[Headline]: Amgen Stock Was a Winner in the Third Quarter. These Solar Shares Were Not.
[Summary]: Amgen was the best-performing stock in both the Dow Jones Industrial Average and Nasdaq 100 in the third quarter, while Zions Bancorp, up 32%, was the top stock in the S&P 500.

Some recent basic financials of AMGN, reported at 2023-09-30, are presented below:

[Basic Financials]:

assetTurnoverTTM: 0.3207
bookValue: 7656
cashRatio: 2.0491329479768785
currentRatio: 2.8593
ebitPerShare: 3.8848
eps: 3.2156
ev: 168202.84
fcfMargin: 0.3639
fcfPerShareTTM: 17.5308
grossMargin: 0.7385
inventoryTurnoverTTM: 1.4407
longtermDebtTotalAsset: 0.6521
longtermDebtTotalCapital: 0.8667
longtermDebtTotalEquity: 7.7116
netDebtToTotalCapital: 0.3776
netDebtToTotalEquity: 3.3604
netMargin: 0.2506
operatingMargin: 0.3028
payoutRatioTTM: 0.589
pb: 18.6097
peTTM: 18.8311
pfcfTTM: 15.1909
pretaxMargin: 0.2821
psTTM: 5.3097
quickRatio: 2.5629
receivablesTurnoverTTM: 4.6784
roaTTM: 0.0904
roeTTM: 1.2908
roicTTM: 0.123
rotcTTM: 0.147
salesPerShare: 12.8309
sgaToSale: 0.2615
totalDebtToEquity: 7.8981
totalDebtToTotalAsset: 0.6679
totalDebtToTotalCapital: 0.8876
totalRatio: 1.0924

Based on all the information before 2023-10-01, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-10-01 to 2023-10-08) is down by 0-1%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen disclosed a large stake in recent IPO Neumora Therapeutics, indicating a profitable investment for the company.
2. Amgen has the potential to break into the obesity market, which is a significant and growing market in the pharmaceutical industry.

[Potential Concerns]:
1. The FTC's intervention in merger deals, which could potentially spook investors and impact Amgen's stock price.
2. The increasing demand for obesity drugs may lead to intense competition among biotech companies, which could affect Amgen's market share.

[Prediction & Analysis]:
Based on the positive developments and potential concerns, it is expected that Amgen's stock price may experience a slight decline of around 0-1% for the upcoming week. While the company's stake in Neumora Therapeutics and potential entry into the obesity market are positive factors, the potential impact of the FTC's intervention and increasing competition in the obesity drug market pose concerns. Additionally, the overall stock market sentiment and investor behavior can also influence the stock price. Therefore, a modest decline is forecasted, taking into consideration both the positive and potential negative factors surrounding Amgen Inc."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 165990.80 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-09-24 to 2023-10-01, AMGN's stock price increased from 265.61 to 266.66. Company news during this period are listed below:

[Headline]: Amgen Inc. stock falls Monday, underperforms market
[Summary]: Shares of Amgen Inc. shed 0.31% to $266.86 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index...

[Headline]: Amgen Inc. stock falls Wednesday, underperforms market
[Summary]: Shares of Amgen Inc. shed 0.02% to $268.98 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index...

[Headline]: Earn Double-Digit Income With Options (October 2023)
[Summary]: Earning a decent income from investments higher than the inflation rate is challenging. Check out how we formulate a sustainable and repeatable options income strategy.

[Headline]: Amgen Inc. stock rises Thursday, outperforms market
[Summary]: Shares of Amgen Inc. inched 0.68% higher to $270.82 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...

[Headline]: Amgen Stock Was a Winner in the Third Quarter. These Solar Shares Were Not.
[Summary]: Amgen was the best-performing stock in both the Dow Jones Industrial Average and Nasdaq 100 in the third quarter, while Zions Bancorp, up 32%, was the top stock in the S&P 500.

From 2023-10-01 to 2023-10-08, AMGN's stock price decreased from 266.66 to 265.38. Company news during this period are listed below:

[Headline]: October Dogs Of The Dow: 3 Buyable, 7 Watchable
[Summary]: Discover how the Dow Jones adds and selects stocks, the highest-yielding stocks in October, and the leading performers in the Dow Industrial Index. Click for more.

[Headline]: Amgen Inc. stock falls Tuesday, underperforms market
[Summary]: Shares of Amgen Inc. slipped 1.99% to $261.01 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...

[Headline]: Gilead Sciences: A Healthy Buy With Solid Dividend
[Summary]: Gilead Sciences has outperformed the S&P 500 with a 19% total return since my last Buy rating in August last year. Learn why GILD stock is a buy.

[Headline]: UPDATE 2-US FDA panel says Amgen lung cancer drug data cannot be relied on
[Summary]: Advisers to the U.S. Food and Drug Administration on Thursday found that data from a late-stage trial of Amgen's Lumakras could not be relied on, raising questions about the agency's upcoming decision on whether to grant traditional approval of the drug for a type of advanced lung cancer.  The drug was approved by the FDA in 2021 under an accelerated pathway, with confirmatory data a condition for gaining traditional approval.  The main goal of the confirmatory study was progression-free survival (PFS), or how long before the disease begins to worsen, but the FDA questioned some methods used in conducting the trial.

[Headline]: UPDATE 2-Amgen completes $27.8 bln Horizon Therapeutics deal
[Summary]: Amgen said on Friday it had completed the $27.8 billion acquisition of Horizon Therapeutics after it received the go-ahead from the U.S. Federal Trade Commission (FTC) last month on certain conditions.  Under the settlement terms with the FTC following its lawsuit to block the deal, Amgen is prevented from using anti-competitive tactics to extend the market dominance of Horizon's fast-growing thyroid eye disease treatment Tepezza and gout drug Krystexxa.  The FTC's antitrust lawsuit had raised concerns over increased oversight on mergers and acquisitions in a sector that often turns to consolidation to power future growth as patents on older treatments expire.

Some recent basic financials of AMGN, reported at 2023-09-30, are presented below:

[Basic Financials]:

assetTurnoverTTM: 0.3207
bookValue: 7656
cashRatio: 2.0491329479768785
currentRatio: 2.8593
ebitPerShare: 3.8848
eps: 3.2156
ev: 168202.84
fcfMargin: 0.3639
fcfPerShareTTM: 17.5308
grossMargin: 0.7385
inventoryTurnoverTTM: 1.4407
longtermDebtTotalAsset: 0.6521
longtermDebtTotalCapital: 0.8667
longtermDebtTotalEquity: 7.7116
netDebtToTotalCapital: 0.3776
netDebtToTotalEquity: 3.3604
netMargin: 0.2506
operatingMargin: 0.3028
payoutRatioTTM: 0.589
pb: 18.6097
peTTM: 18.8311
pfcfTTM: 15.1909
pretaxMargin: 0.2821
psTTM: 5.3097
quickRatio: 2.5629
receivablesTurnoverTTM: 4.6784
roaTTM: 0.0904
roeTTM: 1.2908
roicTTM: 0.123
rotcTTM: 0.147
salesPerShare: 12.8309
sgaToSale: 0.2615
totalDebtToEquity: 7.8981
totalDebtToTotalAsset: 0.6679
totalDebtToTotalCapital: 0.8876
totalRatio: 1.0924

Based on all the information before 2023-10-08, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-10-08 to 2023-10-15) is up by more than 5%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen completed a $27.8 billion acquisition of Horizon Therapeutics, expanding its portfolio and potential for future growth.
2. Amgen's stock was the best-performing in the Dow Jones Industrial Average and Nasdaq 100 in the third quarter.

[Potential Concerns]:
1. Data from a late-stage trial of Amgen's drug, Lumakras, was deemed unreliable by the US FDA panel, raising uncertainty about the drug's approval for advanced lung cancer treatment.
2. The FTC imposed certain conditions on the Horizon Therapeutics acquisition, potentially limiting Amgen's ability to extend market dominance for certain treatments.

[Prediction & Analysis]:
Based on the positive developments and potential concerns, as well as the recent stock price movement, it is predicted that Amgen Inc's stock price will decrease by more than 5% in the upcoming week. The completion of the Horizon Therapeutics deal and the strong performance in the third quarter are positive factors that may contribute to the stock price. However, the concerns surrounding the reliability of Lumakras data and the imposed conditions by the FTC on the acquisition could weigh on investor sentiment and potentially lead to a decline in the stock price. Additionally, the overall market conditions and any significant news within the biotechnology sector may also impact the stock price of Amgen Inc."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 165990.80 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-10-01 to 2023-10-08, AMGN's stock price decreased from 266.66 to 265.38. Company news during this period are listed below:

[Headline]: Large-scale proteomics in population-based studies from UK and Iceland
[Summary]: In a paper released today, deCODE Genetics' scientists shared their findings from a plasma proteomics study performed using affinity-based methods. They analyzed the proteins in the context of diseases and diversity in the sequence of the genome and compared measurements made using two platforms of thousands of proteins in samples from large groups from the UK Biobank and Iceland.

[Headline]: Top Research Reports for Amgen, ServiceNow & RTX
[Summary]: Today's Research Daily features new research reports on 16 major stocks, including Amgen Inc. (AMGN), ServiceNow, Inc. (NOW) and RTX Corporation (RTX).

[Headline]: Amgen (AMGN) Surpasses Market Returns: Some Facts Worth Knowing
[Summary]: Amgen (AMGN) reachead $265.44 at the closing of the latest trading day, reflecting a +1.7% change compared to its last close.

[Headline]: Pharma Giants Combine Forces to Fight New M&A Rules
[Summary]: Meet the anti-antitrust coalition. With a looming overhaul of US merger-and-acquisition law set to reshape the economics of the M&A-heavy...

[Headline]: AMGEN COMPLETES ACQUISITION OF HORIZON THERAPEUTICS PLC
[Summary]: Amgen (NASDAQ: AMGN) today announced that it has completed its acquisition of Horizon Therapeutics plc for $116.50 per share in cash, representing a transaction equity value of approximately $27.8 billion.

From 2023-10-08 to 2023-10-15, AMGN's stock price increased from 265.38 to 281.88. Company news during this period are listed below:

[Headline]: SCHD: A Magnificent Buy At This Time
[Summary]: The Schwab U.S. Dividend Equity ETF holds well-diversified, high-quality stocks with economies of scale. Explore more details here.

[Headline]: Amgen's Acquisition Of Horizon Means The Stock Is A Buy
[Summary]: Amgen strengthens its inflammation portfolio and expands globally with the $27.8 billion acquisition of Horizon. Find out if AMGN stock is a buy.

[Headline]: Amgen Stock Surges To 10-Month High, Up 5% On An Unexpected Upgrade
[Summary]: Amgen stock snagged an upgrade Wednesday and surged to a 10-month high as one analyst examined the biotech behemoth's post-Horizon future.

[Headline]: Better Passive Income Snowball: SCHD Or DIVO?
[Summary]: We compare two potential core ETFs for building a passive income snowball. Click here to learn which one is a better fit for the investing strategy.

[Headline]: (AMGN) Rises As Market Takes a Dip: Key Facts
[Summary]: In the closing of the recent trading day, Amgen (AMGN) stood at $285.04, denoting a +0.51% change from the preceding trading day.

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-10-15, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-10-15 to 2023-10-22) is down by 1-2%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Completion of acquisition of Horizon Therapeutics plc: Amgen's acquisition of Horizon Therapeutics for $27.8 billion expands their inflammation portfolio and provides opportunities for global growth.
2. Stock price surge and upgrade following Horizon acquisition: Amgen's stock surged to a 10-month high and received an unexpected upgrade, indicating market confidence in the company's future prospects.

[Potential Concerns]:
1. Lack of basic financials reported: Not having access to the latest financial information can limit the ability to assess the company's financial health and performance.

[Prediction & Analysis]:
Based on the positive developments of the completion of the Horizon Therapeutics acquisition and the subsequent stock price surge and upgrade, there appears to be positive sentiment surrounding Amgen Inc. However, the lack of reported basic financials raises concerns about the company's financial performance.

Considering these factors, coupled with the fact that the stock price had already seen a significant increase in the previous week, it is reasonable to predict a slight decrease in Amgen's stock price for the upcoming week. Therefore, my prediction for the stock price movement of Amgen Inc for the upcoming week (2023-10-15 to 2023-10-22) is a decline of around 1-2%."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 165990.80 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-10-15 to 2023-10-22, AMGN's stock price decreased from 281.88 to 276.63. Company news during this period are listed below:

[Headline]: Will Amgen (AMGN) Beat Estimates Again in Its Next Earnings Report?
[Summary]: Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

[Headline]: Morgan Stanley Reiterates AMGEN (AMGN) Equal-Weight Recommendation
[Summary]: 

[Headline]: Argus Research Maintains AMGEN (AMGN) Buy Recommendation
[Summary]: 

[Headline]: AMGEN PRESENTS NEW TARLATAMAB DATA IN SMALL CELL LUNG CANCER
[Summary]: Amgen (NASDAQ:AMGN) today announced results from the global Phase 2 DeLLphi-301 study, evaluating tarlatamab, an investigational delta-like ligand 3 (DLL3) targeting BiTE® (bispecific T-cell engager) molecule, in patients with advanced stage small cell lung cancer (SCLC) who had failed two or more prior lines of treatment. The data are being presented today at 3:20 PM CEST at a Proffered Paper session as a late-breaking oral presentation (LBA92) during the European Society for Medical Oncology (

[Headline]: Amgen Inc. stock outperforms market despite losses on the day
[Summary]: Shares of Amgen Inc. dropped 0.64% to $278.81 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-10-22, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-10-22 to 2023-10-29) is down by more than 5%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen has an impressive earnings surprise history, indicating good performance in previous quarters.
2. Amgen presented positive data from a Phase 2 study evaluating tarlatamab, a potential treatment for advanced stage small cell lung cancer, which could indicate promising future developments in the company's pipeline.

[Potential Concerns]:
1. Lack of detailed financial information, making it difficult to assess the company's current financial health and performance.
2. The stock price of Amgen dropped during the analyzed period despite positive news, suggesting potential market challenges and concerns that may weigh on the stock.

[Prediction & Analysis]:
Based on the available information and analysis, it is predicted that Amgen's stock price for the upcoming week (2023-10-22 to 2023-10-29) will decrease by more than 5%. Despite the positive developments, the lack of detailed financials and the recent decline in stock price create uncertainty and potentially negative sentiment among investors. Additionally, the overall rough trading session for the stock market during the analyzed period may indicate broader market challenges that could affect Amgen's stock price. Investors may choose to be cautious, leading to a downward pressure on the stock."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 165990.80 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-10-15 to 2023-10-22, AMGN's stock price decreased from 281.88 to 276.63. Company news during this period are listed below:

[Headline]: Will Amgen (AMGN) Beat Estimates Again in Its Next Earnings Report?
[Summary]: Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

[Headline]: Morgan Stanley Reiterates AMGEN (AMGN) Equal-Weight Recommendation
[Summary]: 

[Headline]: PBYI vs. AMGN: Which Stock Is the Better Value Option?
[Summary]: PBYI vs. AMGN: Which Stock Is the Better Value Option?

[Headline]: 5 Biotech Stocks Set to Outpace Q3 Earnings Estimates
[Summary]: Let us look at some biotech stocks, AMGN, BIIB, GSK, PRTA and VRTX, which are poised to beat on third-quarter earnings.

[Headline]: Amgen Inc. stock underperforms Thursday when compared to competitors
[Summary]: Shares of Amgen Inc. shed 1.05% to $280.60 Thursday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...

From 2023-10-22 to 2023-10-29, AMGN's stock price decreased from 276.63 to 259.53. Company news during this period are listed below:

[Headline]: The Zacks Analyst Blog Highlights Apple, Amgen, Becton, Dickinson, UnitedHealth and Verisk
[Summary]: Apple, Amgen, Becton, Dickinson, UnitedHealth and Verisk are included in this Analyst Blog.

[Headline]: Amgen Inc. stock falls Monday, underperforms market
[Summary]: Shares of Amgen Inc. shed 2.06% to $273.06 Monday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...

[Headline]: Amgen to Lay Off 350 U.S. Employees of Horizon Therapeutics
[Summary]: By Joseph Walker Amgen is laying off about 350 U.S. employees of Horizon Therapeutics, the drugmaker that Amgen bought in a $27.8 billion deal that closed...

[Headline]: Hematology/Oncology Update ESMO 2023
[Summary]: The following slide deck was published by Amgen Inc.

[Headline]: UPDATE 4-AbbVie takes $2.1 bln charge on cancer drug ahead of US price negotiation
[Summary]: AbbVie, girding for government price negotiations on its big-selling cancer drug Imbruvica, on Friday disclosed a $2.1 billion charge related to an expected drop in revenue once the new price for U.S. Medicare patients goes into effect.  The Illinois-based drugmaker's leukemia pill in August was selected as one of the 10 drugs subject to the first-ever price negotiations by U.S. Medicare insurance plans with a stated government goal of saving $25 billion per year on drug costs by 2031.  While new prices for the first 10 drugs have yet to be negotiated and will not go into effect until 2026, AbbVie said it had used an undisclosed placeholder price that led it to estimate ""a significant decrease in the estimated future cash flows"" from the drug.

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-10-29, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-10-29 to 2023-11-05) is up by 3-4%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen has an impressive earnings surprise history, which indicates strong financial performance.
2. Amgen is included in the list of biotech stocks poised to beat third-quarter earnings estimates, suggesting positive market sentiment.

[Potential Concerns]:
1. The stock underperformed its competitors in the last week, which may indicate weakening investor confidence.
2. Amgen's stock price fell due to an all-around poor trading session, reflecting market volatility and uncertainty.

[Prediction & Analysis]:
Based on the positive developments, such as the strong earnings surprise history and being poised to beat earnings estimates, it is likely that Amgen will continue to demonstrate solid financial performance. However, the stock's recent underperformance compared to its competitors and the general poor trading session in the market may hinder its near-term growth potential.

Considering these factors, and assuming a slightly optimistic view, I predict that Amgen's stock price will increase by around 3-4% in the upcoming week. This prediction takes into account the positive developments and recognizes the potential concerns and market volatility as factors that may limit the stock's growth. Investors should closely monitor the market conditions and company news to assess any potential changes in the stock price movement."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 165990.80 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-10-29 to 2023-11-05, AMGN's stock price increased from 259.53 to 267.75. Company news during this period are listed below:

[Headline]: Amgen Boosts Revenue Guidance. But the Stock Trades Lower.
[Summary]: The biotechnology company beat third-quarter adjusted earnings estimates but fell a bit short on sales.

[Headline]: Here's What Key Metrics Tell Us About Amgen (AMGN) Q3 Earnings
[Summary]: Although the revenue and EPS for Amgen (AMGN) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

[Headline]: GSK Reports Earnings Wednesday. Here’s What to Expect.
[Summary]: The company will for the first time report sales of Arexvy, its new RSV vaccine that launched this fall.

[Headline]: Company News for Nov 01, 2023
[Summary]: Companies In The Article Are: AMGN, NVDA, RGEN, COCO

[Headline]: AMGEN PRESENTS NEW DATA THAT SHOW BLOOD PRESSURE DECREASES FOR ADULTS TREATED WITH KRYSTEXXA® (PEGLOTICASE)
[Summary]: Amgen (NASDAQ:AMGN) today announced new data for KRYSTEXXA® (pegloticase) showing a decrease in blood pressure during treatment of adults living with chronic gout refractory to oral urate-lowering treatment − uncontrolled gout − both with and without chronic kidney disease (CKD). The data will be presented at the American Society of Nephrology Kidney Week, taking place Nov. 2-5, in Philadelphia.

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-11-05, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-11-05 to 2023-11-12) is down by 0-1%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen Inc. beat third-quarter adjusted earnings estimates, indicating strong financial performance.
2. The company presented new data showing a decrease in blood pressure for adults treated with its drug KRYSTEXXA, which demonstrates the effectiveness of their products in treating chronic gout refractory to oral urate-lowering treatment.
3. Amgen Inc. boosted its revenue guidance, suggesting positive outlook and growth prospects for the company.

[Potential Concerns]:
1. Although Amgen Inc. beat adjusted earnings estimates, it fell slightly short on sales, which could raise concerns about the company's ability to generate sufficient revenue.
2. The upcoming earnings report from GSK, which includes sales of a competing RSV vaccine, Arexvy, may impact Amgen Inc.'s market share and revenue in the future.

[Prediction & Analysis]:
Considering the positive developments, including the strong financial performance and the effectiveness of their products, combined with the boost in revenue guidance, Amgen Inc. appears to be on a positive trajectory. However, the slightly lower-than-expected sales and potential competition from GSK's RSV vaccine could limit the company's growth potential.

Based on this analysis, coupled with the given prediction for a 0-1% decrease in stock price, it can be inferred that there may be some uncertainties causing investors to take a cautious stance. This could be due to concerns about the company's ability to meet sales targets or potential market share loss. However, overall, the positive developments are likely to provide support to the stock price, mitigating the potential negative impact."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 165990.80 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-10-15 to 2023-10-22, AMGN's stock price decreased from 281.88 to 276.63. Company news during this period are listed below:

[Headline]: AMGEN TO PRESENT NEW RESEARCH FROM ONCOLOGY PORTFOLIO AND PIPELINE AT ESMO 2023
[Summary]: Amgen (NASDAQ:AMGN) today announced the presentation of new data across its broad oncology portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress 2023, taking place from October 20-24 in Madrid. Results from Amgen-sponsored and collaborative studies, including two late-breaking oral presentations, will feature data in a range of tough-to-treat cancers.

[Headline]: Dividend Income Update September 2023
[Summary]: With the start of the final quarter of 2023, it’s time to take a look back at my previous month of dividend income.

[Headline]: Amgen (AMGN) Stock Moves -0.3%: What You Should Know
[Summary]: Amgen (AMGN) closed the most recent trading day at $283.58, moving -0.3% from the previous trading session.

[Headline]: Dow drops nearly 100 points on losses in shares of Merck, Amgen
[Summary]: Shares of Merck and Amgen are posting losses Thursday morning, dragging the Dow Jones Industrial Average into negative territory. The Dow was most recently...

[Headline]: AMGEN PRESENTS NEW TARLATAMAB DATA IN SMALL CELL LUNG CANCER
[Summary]: Amgen (NASDAQ:AMGN) today announced results from the global Phase 2 DeLLphi-301 study, evaluating tarlatamab, an investigational delta-like ligand 3 (DLL3) targeting BiTE® (bispecific T-cell engager) molecule, in patients with advanced stage small cell lung cancer (SCLC) who had failed two or more prior lines of treatment. The data are being presented today at 3:20 PM CEST at a Proffered Paper session as a late-breaking oral presentation (LBA92) during the European Society for Medical Oncology (

From 2023-10-22 to 2023-10-29, AMGN's stock price decreased from 276.63 to 259.53. Company news during this period are listed below:

[Headline]: Hematology/Oncology Update ESMO 2023
[Summary]: The following slide deck was published by Amgen Inc.

[Headline]: 20 Countries with Lowest Rates of Cancer
[Summary]: In this article, we will be taking a look at the 20 countries with lowest rates of cancer. If you want to skip our analysis of the oncology industry, then head straight to 5 Countries with Lowest Rates of Cancer. Cancer— a disease in which some of the body’s cells grow uncontrollably and spread to […]

[Headline]: Amgen (AMGN) to Report Q3 Earnings: Will It Beat Estimates?
[Summary]: Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.

[Headline]: Amgen Inc. stock falls Friday, underperforms market
[Summary]: Shares of Amgen Inc. shed 3.02% to $261.57 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...

[Headline]: 2 Dow Jones Dividend Stocks to Buy Hand Over Fist Right Now
[Summary]: Dividend stocks have not performed particularly well in 2023, and for good reason.  With many financial institutions offering safer alternatives, such as money market accounts and certificates of deposit, with annualized rates above 5%, there's been little reason for investors to stomach the volatility associated with equities.  Dividend stocks have a long history of outperforming most other asset classes over holding periods of 20 years or longer.

From 2023-10-29 to 2023-11-05, AMGN's stock price increased from 259.53 to 267.75. Company news during this period are listed below:

[Headline]: Drug, Biotech Stocks' Q3 Earnings Due on Oct 31: AMGN, PFE, INCY
[Summary]: Let's take a look at three biotech/drug companies, AMGN, PFE and INCY, slated to release quarterly results on Oct 31.

[Headline]: Amgen Boosts Revenue Guidance, but the Stock Is Falling
[Summary]: The biotechnology company beat third-quarter adjusted earnings estimates but fell a bit short on sales.

[Headline]: Amgen Boosts Revenue Guidance. But the Stock Trades Lower.
[Summary]: The biotechnology company beat third-quarter adjusted earnings estimates but fell a bit short on sales.

[Headline]: Never Mind Covid, Investors Want a Pfizer Obesity Pill
[Summary]: It is little wonder, then, that investors were hoping Pfizer could jump to the winning camp with an obesity pill.  “Not one mention [of danuglipron] in the prepared remarks from Pfizer,” noted  Will Sevush,  a healthcare strategist for Jefferies.  Before today’s earnings,  David Risinger,  a Leerink Partners analyst, had written that Pfizer might even release data from its mid-stage study alongside the earnings results as soon as Tuesday.

[Headline]: The Amgen Inc (AMGN) Company: A Short SWOT Analysis
[Summary]: Unveiling the Strengths and Challenges: A Deep Dive into Amgen Inc (AMGN) SWOT Analysis

From 2023-11-05 to 2023-11-12, AMGN's stock price decreased from 267.75 to 265.22. Company news during this period are listed below:

[Headline]: November Dogs Of The Dow: 3 Buyable, 4 Watchable
[Summary]: Learn about the Dow Jones Industrial Average and the top-performing stocks in November. Click to see our exclusive list of dividend stocks we consider buyable now.

[Headline]: Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
[Summary]: Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

[Headline]: Amgen Inc. stock falls Tuesday, underperforms market
[Summary]: Shares of Amgen Inc. slipped 0.63% to $271.11 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...

[Headline]: Amgen Inc. stock rises Wednesday, outperforms market
[Summary]: Shares of Amgen Inc. inched 0.79% higher to $273.26 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P...

[Headline]: Why You Should Aim For $2 Million For Retirement
[Summary]: Retirement goals should be set based on individual situations and factors like your pre-retirement earnings. Explore more details here.

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-11-12, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-11-12 to 2023-11-19) is up by 0-1%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen presented new research from its oncology portfolio and pipeline at the ESMO 2023 Congress, showcasing data in tough-to-treat cancers.
2. Amgen presented new data from the Phase 2 DeLLphi-301 study, evaluating tarlatamab in patients with advanced stage small cell lung cancer, which could indicate potential breakthroughs in treatment.

[Potential Concerns]:
1. The stock price of Amgen decreased during the period, potentially reflecting negative sentiment in the market for the company's performance or industry conditions.
2. Amgen fell short on sales in its third-quarter earnings report, which could indicate potential sales growth challenges.

[Prediction & Analysis]:
Based on the positive developments, including the new research presented at the ESMO 2023 Congress and the potential breakthroughs in small cell lung cancer treatment, it suggests that the company is actively working on innovative solutions and expanding its oncology portfolio. These developments may contribute to positive sentiment among investors and could drive the stock price higher in the upcoming week.

However, considering the potential concerns such as the decrease in stock price and falling short on sales in the third quarter, it is important to note that there might be some lingering concerns among investors and market participants. These factors could potentially limit the extent of the stock price increase.

Considering the overall analysis, it is predicted that the stock price of Amgen (AMGN) could increase by 0-1% in the upcoming week."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 165990.80 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-11-12 to 2023-11-19, AMGN's stock price increased from 265.22 to 265.39. Company news during this period are listed below:

[Headline]: Amgen: Buy In Stable Fundamental And Technical Price Growth
[Summary]: Amgen's Q3 2023 financial performance showed increased total revenues and product sales, driven by volume growth and strong international markets. Click here to read my analysis.

[Headline]: O'Keefe Stevens Advisory Q3 2023 Update
[Summary]: At the end of Q3 2023, O'Keefe Stevens Advisory's top 5 holdings represented ~27% of assets, down from 35% at the end of Q2. Click here to read the full fund letter. 

[Headline]: Amgen : LUMAKRAS® (sotorasib) Dose Comparison Study Results
[Summary]: LUMAKRAS® Dose Comparison Study Results Today, during an ESMO Plenary Virtual Session, Amgen presented data from the LUMAKRAS® 960 mg versus 240 mg dose comparison study in...

[Headline]: Amgen Inc. stock falls Friday, underperforms market
[Summary]: Shares of Amgen Inc. shed 1.34% to $265.39 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index...

[Headline]: 18 Best-Performing Dow Stocks in 2023
[Summary]: In this article, we will take a look at the 18 best-performing Dow stocks in 2023. To see more such companies, go directly to 5 Best-Performing Dow Stocks in 2023. The economy and stock markets have defied almost every prediction and estimate in 2023. When the year started there was almost a consensus among notable […]

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-11-19, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-11-19 to 2023-11-26) is up by 0-1%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen's Q3 2023 financial performance showed increased total revenues and product sales, driven by volume growth and strong international markets.
2. Amgen presented positive data from the LUMAKRAS® dose comparison study, highlighting the potential efficacy of the drug.

[Potential Concerns]:
1. Amgen's stock underperformed the market during the previous week, despite overall favorable trading session for the stock market.
2. No basic financials have been reported, making it difficult to evaluate the company's financial health and stability.

[Prediction & Analysis]:
Considering the positive developments, such as the impressive Q3 financial performance and promising results from the LUMAKRAS® dose comparison study, it is likely that Amgen's stock price will show positive movement in the upcoming week. These factors indicate the company's continued growth and potential for success in the biotechnology sector. However, the underperformance of Amgen's stock in the previous week could raise concerns and lead to some volatility in the short term.

Given the lack of basic financials, it is challenging to assess the overall financial health of the company, which could impact investors' confidence. Additionally, external market factors and industry dynamics should be considered when evaluating the stock's potential movement. Therefore, considering the positive developments and potential concerns, it is predicted that Amgen's stock price will increase by 0-1% in the upcoming week."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 165990.80 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-11-19 to 2023-11-26, AMGN's stock price increased from 265.39 to 265.46. Company news during this period are listed below:

[Headline]: Amgen Inc. stock underperforms Monday when compared to competitors
[Summary]: Shares of Amgen Inc. dropped 0.02% to $265.35 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...

[Headline]: Billionaire Steven Cohen’s Top High Dividend Stock Picks
[Summary]: In this article, we discuss billionaire Steve Cohen’s top high-dividend stock picks. You can skip our detailed analysis of Point72 Asset Management’s holding and recent developments, and go directly to read Billionaire Steven Cohen’s Top 5 High Dividend Stock Picks. Steve Cohen is a prominent figure in the world of finance and investing, known for […]

[Headline]: Munger And Buffett Say Invest $100,000 For Financial Freedom: Consider SCHD
[Summary]: Charlie Munger has emphasized the importance of investing $100,000. See why SCHD ETF is a strong investment option for reaching financial freedom.

[Headline]: AbbVie Vs. Amgen: How Peter Lynch Picks Dividend Stocks
[Summary]: This article examines two healthcare stalwarts, AbbVie (ABBV) and Amgen (AMGN) through the lens of Lynch's approach. Check out which stock I prefer.

[Headline]: Amgen Inc. stock outperforms competitors on strong trading day
[Summary]: Shares of Amgen Inc. inched 0.67% higher to $264.59 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P...

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-11-26, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-11-26 to 2023-12-03) is up by 2-3%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen Inc. stock outperformed its competitors on a strong trading day, indicating positive market sentiment.
2. Billionaire Steven Cohen's top high-dividend stock picks included Amgen Inc., suggesting confidence in the company's future prospects.

[Potential Concerns]:
1. Amgen Inc. stock underperformed its competitors on a trading day, which might indicate weakness or lackluster performance compared to industry peers.

[Prediction & Analysis]:
Based on the positive developments and potential concerns, it is likely that Amgen Inc.'s stock price will increase by 2-3% in the upcoming week. The outperformance of Amgen Inc. stock on a strong trading day, along with the endorsement by billionaire Steven Cohen, highlights positive sentiment and potential growth opportunities for the company. However, the underperformance on another trading day raises concerns about relative competitiveness and performance. Nevertheless, considering the overall positive developments, it is expected that Amgen Inc.'s stock price will experience a modest increase in the upcoming week."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 165990.80 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-11-12 to 2023-11-19, AMGN's stock price increased from 265.22 to 265.39. Company news during this period are listed below:

[Headline]: Amgen Inc. stock rises Tuesday, still underperforms market
[Summary]: Shares of Amgen Inc. rose 1.25% to $270.02 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index...

[Headline]: Amgen : LUMAKRAS® (sotorasib) Dose Comparison Study Results
[Summary]: LUMAKRAS® Dose Comparison Study Results Today, during an ESMO Plenary Virtual Session, Amgen presented data from the LUMAKRAS® 960 mg versus 240 mg dose comparison study in...

[Headline]: Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
[Summary]: Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

[Headline]: Amgen Inc. stock falls Friday, underperforms market
[Summary]: Shares of Amgen Inc. shed 1.34% to $265.39 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index...

[Headline]: 18 Best-Performing Dow Stocks in 2023
[Summary]: In this article, we will take a look at the 18 best-performing Dow stocks in 2023. To see more such companies, go directly to 5 Best-Performing Dow Stocks in 2023. The economy and stock markets have defied almost every prediction and estimate in 2023. When the year started there was almost a consensus among notable […]

From 2023-11-19 to 2023-11-26, AMGN's stock price increased from 265.39 to 265.46. Company news during this period are listed below:

[Headline]: 20 Most Valuable Healthcare Companies in the World
[Summary]: In this article, we will look into the 20 most valuable healthcare companies in the world. If you want to skip our detailed analysis, you can go directly to the 5 Most Valuable Healthcare Companies in the World. Healthcare Services Industry: A Market Analysis According to a report by Verified Market Research, the global healthcare […]

[Headline]: Billionaire Steven Cohen’s Top High Dividend Stock Picks
[Summary]: In this article, we discuss billionaire Steve Cohen’s top high-dividend stock picks. You can skip our detailed analysis of Point72 Asset Management’s holding and recent developments, and go directly to read Billionaire Steven Cohen’s Top 5 High Dividend Stock Picks. Steve Cohen is a prominent figure in the world of finance and investing, known for […]

[Headline]: AbbVie Vs. Amgen: How Peter Lynch Picks Dividend Stocks
[Summary]: This article examines two healthcare stalwarts, AbbVie (ABBV) and Amgen (AMGN) through the lens of Lynch's approach. Check out which stock I prefer.

[Headline]: Bristol-Myers Squibb: A Tough But Cheap Spot
[Summary]: Learn about the challenges facing Bristol-Myers Squibb as it deals with loss of exclusivity, growth concerns, and other issues. Click here for more on BMY stock.

[Headline]: Merck: Keytruda Patent Expiry Nears With Replacement Yet To Be Found
[Summary]: For now, Merck's prospects have somewhat dimmed, with management engaging on expensive partnerships to boost its pipelines. Learn why we rate MRK stock a hold.

From 2023-11-26 to 2023-12-03, AMGN's stock price increased from 265.46 to 272.45. Company news during this period are listed below:

[Headline]: Amgen Inc. stock falls Monday, underperforms market
[Summary]: Shares of Amgen Inc. dropped 0.45% to $264.27 Monday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...

[Headline]: Amgen Inc. (AMGN) Presents at 6th Annual Evercore ISI HealthCONx Conference (Transcript)
[Summary]: Amgen Inc. (NASDAQ:NASDAQ:AMGN) 6th Annual Evercore ISI HealthCONx Conference November 29, 2023 9:10 AM ETCompany ParticipantsPeter Griffith - EVP and...

[Headline]: Top Stock Reports for McDonald's, Amgen & NextEra Energy
[Summary]: Today's Research Daily features new research reports on 16 major stocks, including McDonald's Corporation (MCD), Amgen Inc. (AMGN) and NextEra Energy, Inc. (NEE).

[Headline]: Amgen Inc. stock underperforms Thursday when compared to competitors despite daily gains
[Summary]: Shares of Amgen Inc. rallied 1.14% to $269.64 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...

[Headline]: Arrowhead Pharmaceuticals: Balance Sheet Concern Needs To Be Addressed
[Summary]: Arrowhead Pharmaceuticals stock drops on balance sheet concerns following fiscal Q3 results. Read why I think positive preclinical results offer hope for ARWR.

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-12-03, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-12-03 to 2023-12-10) is down by 1-2%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen presented data from the LUMAKRAS® dose comparison study, which could potentially strengthen the drug's position in the market.
2. Amgen's stock price has been steadily increasing over the past few weeks, indicating investor confidence in the company.

[Potential Concerns]:
1. Amgen's stock underperformed the market on certain trading sessions, suggesting potential volatility and investor uncertainty.
2. The poor performance of Amgen's stock on Monday, coupled with concerns raised about the company's balance sheet, could create apprehension among investors.

[Prediction & Analysis]:
Based on the positive developments and potential concerns, as well as the overall market trends, it is predicted that Amgen's stock price may experience a slight decline of 1-2% in the upcoming week (2023-12-03 to 2023-12-10). The mixed performance of the stock in recent sessions, alongside the concerns raised about the balance sheet, may lead to a temporary loss of confidence among investors, resulting in a minor downward movement in the stock price. However, it is important to note that the long-term prospects of Amgen remain positive, particularly considering the positive developments in terms of the LUMAKRAS® dose comparison study."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 165990.80 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-11-26 to 2023-12-03, AMGN's stock price increased from 265.46 to 272.45. Company news during this period are listed below:

[Headline]: 15 Best Drug Stocks To Invest In
[Summary]: In this article, we discuss the 15 best drug stocks to invest in. You can skip our detailed analysis of the drug and pharmaceutical sector and its outlook this year, and go directly to read the 5 Best Drug Stocks To Invest In. Healthcare expands on the defensive concept, encompassing a myriad of companies. This […]

[Headline]: 1 Spectacular Dividend Stock Every Investor Should Consider
[Summary]: Dividend stocks are versatile investments that can serve different purposes in a portfolio.  Others use them to boost their portfolio's performance by reinvesting the dividends to compound their returns over time.  Here is a brief overview of one blue-chip dividend stock that has successfully served both roles (income generation and above-average capital appreciation) over the past 12 years and that also appears more than capable of continuing this tradition for the foreseeable future.

[Headline]: This Stock Hasn't Split Since 1999 — $1,000 Invested Then Would Be Worth A Boatload Today
[Summary]: When investing in the stock market, a history of strong returns should be high on your priority list. Combine this with a positive outlook on the future, and you may have a winner to add to your portfolio. Amgen Inc., an American multinational biopharmaceutical company, fits this mold. The company has a 10-year annualized total return of 13.69% through the end of 2022. And if that's not enough to pique your interest, consider this: It pays out billions of dollars in dividends to investors every

[Headline]: Worried About a Weight-Loss Stock Bubble? Here Are Some Alternatives.
[Summary]: Eli Lilly and Novo Nordisk, riding the wave of enthusiasm for obesity meds, are seeing their stock prices soar. But behind them are coming new therapies from companies for investors that are drawn to the size of the obesity market but put off by the valuations.

[Headline]: Dividend Champion, Contender, And Challenger Highlights: Week Of December 3
[Summary]: A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read more to see the update for the week of December 3.

From 2023-12-03 to 2023-12-10, AMGN's stock price decreased from 272.45 to 269.12. Company news during this period are listed below:

[Headline]: Amgen Inc. stock underperforms Tuesday when compared to competitors
[Summary]: Shares of Amgen Inc. sank 0.61% to $270.87 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...

[Headline]: MoonLake Immunotherapeutics: Poised For Acquisition
[Summary]: MoonLake, a clinical-stage biopharmaceutical company, is gaining attention with its promising nanobody-based therapies for inflammatory diseases. Read more here.

[Headline]: Amgen Inc. stock underperforms Friday when compared to competitors
[Summary]: Shares of Amgen Inc. shed 0.81% to $269.12 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index...

[Headline]: 12 Dow Stocks Billionaires Like The Most
[Summary]: In this piece, we will take a look at the 12 Dow stocks that billionaires like the most. If you don’t want to learn more about the Dow Jones Industrial Average (DJIA), its history, and recent performance, then skip ahead to 5 Dow Stocks Billionaires Like The Most. In its current form today, the Dow […]

[Headline]: No global carbon price? Some companies set their own
[Summary]: BOSTON/DUBAI/SAN FRANCISCO (Reuters) -A growing list of global companies are setting a price or charging themselves for each metric ton of their carbon emissions, looking to shape their investments and business for future pollution taxes or other new climate rules.  Their prices are all over the place, from less than $1 per metric ton of carbon emissions to $1,600, the most of any company worldwide, set by California drugmaker Amgen.  Regulators, too, have offered a range of prices, including the Biden administration's ""social cost"" of carbon, around $200, and a suggestion from the International Monetary Fund that it should be at least $85 by 2030.

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-12-10, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-12-10 to 2023-12-17) is up by 2-3%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen Inc. is recognized as one of the 15 best drug stocks to invest in, highlighting its strong position in the pharmaceutical sector.
2. The company has a history of strong returns, with a 10-year annualized total return of 13.69% through the end of 2022.
3. Amgen Inc. pays out billions of dollars in dividends to investors, indicating its financial stability and commitment to shareholder returns.

[Potential Concerns]:
1. Amgen Inc. underperformed compared to competitors on Tuesday and Friday, suggesting possible challenges in the stock's short-term performance.
2. The company is facing competition from other companies in the obesity medication market, which could impact its market share and revenue.

[Prediction & Analysis]:
Considering the positive developments and potential concerns, it is reasonable to predict that Amgen Inc.'s stock price may have a slight increase of around 2-3% in the upcoming week. The recognition as one of the best drug stocks to invest in and the history of strong returns are positive indicators for investor confidence. Additionally, the company's consistent dividend payouts demonstrate stability and attractiveness to income-seeking investors. However, the underperformance compared to competitors and the competition in the obesity medication market could limit the stock's short-term growth potential. Overall, while the stock may experience some volatility, the positive factors should outweigh the concerns and contribute to a modest price increase."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 165990.80 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-11-26 to 2023-12-03, AMGN's stock price increased from 265.46 to 272.45. Company news during this period are listed below:

[Headline]: Amgen Inc. stock falls Monday, underperforms market
[Summary]: Shares of Amgen Inc. dropped 0.45% to $264.27 Monday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...

[Headline]: 1 Spectacular Dividend Stock Every Investor Should Consider
[Summary]: Dividend stocks are versatile investments that can serve different purposes in a portfolio.  Others use them to boost their portfolio's performance by reinvesting the dividends to compound their returns over time.  Here is a brief overview of one blue-chip dividend stock that has successfully served both roles (income generation and above-average capital appreciation) over the past 12 years and that also appears more than capable of continuing this tradition for the foreseeable future.

[Headline]: AWS expands big pharma partnerships in manufacturing, AI, and R&D
[Summary]: Pfizer and Amazon Web Services are just another example of how artificial intelligence is working in the background in healthcare.

[Headline]: Amgen Inc. stock underperforms Thursday when compared to competitors despite daily gains
[Summary]: Shares of Amgen Inc. rallied 1.14% to $269.64 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...

[Headline]: Weight-Loss Stocks Are Getting Pricey. Time to Worry About a Bubble?
[Summary]: Eli Lilly and Novo Nordisk, riding the wave of enthusiasm for obesity meds, are seeing their stock prices soar. But behind them are coming new therapies from companies for investors that are drawn to the size of the obesity market but put off by the valuations.

From 2023-12-03 to 2023-12-10, AMGN's stock price decreased from 272.45 to 269.12. Company news during this period are listed below:

[Headline]: December Dogs Of The Dow: 3 Buyable, 5 Watchable
[Summary]: Some of these Dow Industrials are too pricey and reveals only skinny dividends. Read here about 3 of the 5 lowest-priced Dogs of the Dow which are ready to buy.

[Headline]: Amgen Inc. stock falls Wednesday, underperforms market
[Summary]: Shares of Amgen Inc. sank 0.56% to $269.35 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...

[Headline]: Amgen (AMGN) Registers a Bigger Fall Than the Market: Important Facts to Note
[Summary]: In the latest trading session, Amgen (AMGN) closed at $269.35, marking a -0.56% move from the previous day.

[Headline]: Amgen (NASDAQ:AMGN) shareholders have earned a 9.8% CAGR over the last five years
[Summary]: If you buy and hold a stock for many years, you'd hope to be making a profit. Furthermore, you'd generally like to see...

[Headline]: Like Dividends? You Should Check Out This Wealth-Creating Income Investment
[Summary]: The Schwab U.S. Dividend Equity ETF focuses on stocks that have historically delivered market-beating total returns.

From 2023-12-10 to 2023-12-17, AMGN's stock price increased from 269.12 to 275.45. Company news during this period are listed below:

[Headline]: Here's Why Amgen (AMGN) is a Strong Value Stock
[Summary]: The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

[Headline]: 1 Biotech Stock That Could Be the Next Amgen
[Summary]: The emergence of genomic medicine as a viable modality could transform this midcap biotech into the next Amgen.

[Headline]: Big Pharma: Why the drug industry faces a 3-front battle with the FTC, Medicare, and the White House
[Summary]: The Biden administration is increasingly focused on finding ways to lower drug prices, putting the drug industry in a three-way battle to defend its ecosystem.

[Headline]: Amgen's (AMGN) Tarlatamab BLA Gets FDA Priority Tag for SCLC
[Summary]: Amgen's (AMGN) BLA for tarlatamab to treat advanced small cell lung cancer gets FDA's priority review. A decision is expected on Jun 12, 2024.

[Headline]: Is Amgen Stock a Buy Now?
[Summary]: Boring businesses can be successful, too.

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-12-17, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-12-17 to 2023-12-24) is up by 3-4%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Expansion of big pharma partnerships with Amazon Web Services (AWS) indicates potential for increased collaboration and technological advancements in manufacturing, AI, and R&D.
2. Company news highlighting Amgen Inc.'s strong dividend track record and wealth-creating income investment showcases the company's ability to deliver consistent returns to shareholders.

[Potential Concerns]:
1. Underperformance of Amgen Inc. stock in comparison to competitors on certain trading sessions raises concerns about the company's market position and ability to outperform industry peers.
2. Rising valuations and potential market bubble in the weight-loss industry may pose a challenge for Amgen Inc. to maintain its growth trajectory.

[Prediction & Analysis]:
Based on the positive developments and potential concerns, as well as the general trend in the market, it is predicted that Amgen Inc.'s stock price will increase by 3-4% in the upcoming week (2023-12-17 to 2023-12-24). 

The expansion of big pharma partnerships and the company's strong dividend track record indicate stability and potential for future growth. Additionally, the overall market trend and positive news flow surrounding Amgen Inc. provide a supportive environment for stock price appreciation. However, it is important to monitor the company's ability to outperform competitors and navigate the potential challenges of market valuations in the weight-loss industry."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 165990.80 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-12-10 to 2023-12-17, AMGN's stock price increased from 269.12 to 275.45. Company news during this period are listed below:

[Headline]: 15 Least Competitive Medical Specialties in America
[Summary]: In this article, we will look at the 15 least competitive medical specialities in America. We have also discussed the state of the healthcare industry in the US. If you want to skip our detailed analysis, head straight to the 5 Least Competitive Medical Specialities in America. Choosing a medical speciality involves a combination of […]

[Headline]: Here's Why We Think Amgen (NASDAQ:AMGN) Might Deserve Your Attention Today
[Summary]: For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

[Headline]: AMGEN ANNOUNCES 2024 FIRST QUARTER DIVIDEND INCREASE TO $2.25 PER SHARE
[Summary]: Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the first quarter of 2024. This is the 12th consecutive year that Amgen has increased its dividend and comes as the Company continues to invest in innovation and deleverage its balance sheet. The dividend will be paid on March 7, 2024, to all stockholders of record as of the close of business on February 16, 2024.

[Headline]: AMGEN TO SPONSOR THE IRISH OPEN
[Summary]: Amgen (NASDAQ:AMGN) today announced it will serve as the title sponsor of the Irish Open starting in 2024, following the acquisition of Horizon Therapeutics plc in October 2023. Horizon Therapeutics, a leading Irish company, began sponsoring the tournament in 2022 as part of a multi-year commitment to the Irish community.

[Headline]: Is Amgen Stock a Buy Now?
[Summary]: Boring businesses can be successful, too.

From 2023-12-17 to 2023-12-24, AMGN's stock price increased from 275.45 to 284.16. Company news during this period are listed below:

[Headline]: XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector
[Summary]: XLV comprises major healthcare industry players and offers a convenient and cost-effective way to invest in the sector. Find out my analysis of XLV ETF.

[Headline]: Amgen upgraded, PepsiCo downgraded: Wall Street's top analyst calls
[Summary]: Amgen upgraded, PepsiCo downgraded: Wall Street's top analyst calls

[Headline]: Amgen Inc. stock outperforms market on strong trading day
[Summary]: Shares of Amgen Inc. rose 1.51% to $279.33 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...

[Headline]: Amgen Inc. stock outperforms competitors on strong trading day
[Summary]: Shares of Amgen Inc. advanced 1.73% to $284.16 Friday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index...

[Headline]: Bristol Myers Squibb: Aggressive M&A, A Riskier Strategy To Fix The Growth Challenge
[Summary]: Bristol Myers Squibb's (BMY) 2023 outlook is tough, with stagnation and a decline in sales expected, along with increasing debt. Click here to read more.

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-12-24, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-12-24 to 2023-12-31) is up by 1-2%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen declared a dividend increase for the first quarter of 2024, highlighting the company's commitment to shareholders and its ability to generate steady cash flow.
2. Amgen announced its sponsorship of the Irish Open, demonstrating the company's engagement with the Irish community and potentially increasing brand visibility.

[Potential Concerns]:
1. Lack of specific positive news related to Amgen's core business or product pipeline during the analyzed period.
2. Market volatility and potential risks associated with the overall healthcare sector.

[Prediction & Analysis]:
Based on the limited information available, the positive developments such as the dividend increase and sponsorship of the Irish Open could generate a positive sentiment among investors. However, the lack of significant news directly related to Amgen's core business or product pipeline raises some concerns. Additionally, market volatility and potential risks within the healthcare sector could impact Amgen's stock price.

Considering these factors, it is predicted that Amgen's stock price may experience a moderate increase of around 1-2% in the upcoming week. This prediction is based on the general positive sentiment surrounding the dividend increase and the potential boost in brand visibility through the sponsorship of the Irish Open. However, investors should closely monitor any developments in the healthcare industry and specific news related to Amgen's products or pipeline that could impact the stock's performance."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 165990.80 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-12-10 to 2023-12-17, AMGN's stock price increased from 269.12 to 275.45. Company news during this period are listed below:

[Headline]: INSIGHT-No global carbon price? Some companies set their own
[Summary]: A growing list of global companies are setting a price or charging themselves for each metric ton of their carbon emissions, looking to shape their investments and business for future pollution taxes or other new climate rules.  Their prices are all over the place, from less than $1 per metric ton of carbon emissions to $1,600, the most of any company worldwide, set by California drugmaker Amgen.

[Headline]: Big Pharma: Why the drug industry faces a 3-front battle with the FTC, Medicare, and the White House
[Summary]: The Biden administration is increasingly focused on finding ways to lower drug prices, putting the drug industry in a three-way battle to defend its ecosystem.

[Headline]: Amgen Inc. stock outperforms market on strong trading day
[Summary]: Shares of Amgen Inc. advanced 2.78% to $281.62 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...

[Headline]: Amgen's (AMGN) Tarlatamab BLA Gets FDA Priority Tag for SCLC
[Summary]: Amgen's (AMGN) BLA for tarlatamab to treat advanced small cell lung cancer gets FDA's priority review. A decision is expected on Jun 12, 2024.

[Headline]: Is Amgen Stock a Buy Now?
[Summary]: Boring businesses can be successful, too.

From 2023-12-17 to 2023-12-24, AMGN's stock price increased from 275.45 to 284.16. Company news during this period are listed below:

[Headline]: Dividend Champion, Contender, And Challenger Highlights: Week Of December 17
[Summary]: Weekly summary of dividend activity for Dividend Champions, Contenders, Challengers. Read more to see the companies with upcoming ex-dividend dates.

[Headline]: Amgen Inc. stock rises Monday, still underperforms market
[Summary]: Shares of Amgen Inc. inched 0.01% higher to $275.48 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500...

[Headline]: US STOCKS-Wall Street ends higher as rate-cut fever lingers
[Summary]: Wall Street extended its rally on Tuesday, advancing on the day as last week's dovish policy pivot from the Federal Reserve continued to reverberate and investors looked ahead to crucial inflation data.  Broad-based gains boosted all three major U.S. stock indexes and nudged the S&P 500 to within 1 percentage point of its all-time closing high reached in January 2022.

[Headline]: Amgen Inc. stock outperforms competitors despite losses on the day
[Summary]: Shares of Amgen Inc. slid 1.17% to $275.18 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...

[Headline]: Bristol Myers Squibb: Aggressive M&A, A Riskier Strategy To Fix The Growth Challenge
[Summary]: Bristol Myers Squibb's (BMY) 2023 outlook is tough, with stagnation and a decline in sales expected, along with increasing debt. Click here to read more.

From 2023-12-24 to 2023-12-31, AMGN's stock price increased from 284.16 to 288.02. Company news during this period are listed below:

[Headline]: US FDA turns down Amgen lung cancer drug Lumakras for full approval
[Summary]: The U.S. Food and Drug Administrationon Tuesday declined to grant traditional approval to Amgen'sLumakras for treating lung cancer patients with aspecific gene mutation, but did not withdraw the...

[Headline]: Amgen’s NDA for Lumakras cancer treatment resulted in complete response letter
[Summary]: Amgen Inc. said Tuesday that the regulatory review of its supplemental new drug application seeking full approval of Lumakras resulted in a “complete...

[Headline]: Healthcare Stocks Had a Terrible 2023. Things Are Looking Up.
[Summary]: Things could hardly have gone worse for healthcare investors this year.

[Headline]: Amgen (AMGN) Stock Moves -0.15%: What You Should Know
[Summary]: The latest trading day saw Amgen (AMGN) settling at $288.02, representing a -0.15% change from its previous close.

[Headline]: Chevron, Kimberly-Clark Among 14 Companies To Announce Dividend Increases In January
[Summary]: Investors celebrate double-digit increases for Mastercard and Broadcom.

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-12-31, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-12-31 to 2024-01-07) is up by more than 5%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen's BLA for Tarlatamab to treat advanced small cell lung cancer received FDA's priority review, indicating potential for approval and market demand.
2. Amgen set its own carbon price, demonstrating its commitment to addressing climate change and potentially positioning the company favorably in the emerging market for carbon credits.

[Potential Concerns]:
1. The drug industry is facing increasing scrutiny from the FTC, Medicare, and the White House, which could result in regulatory challenges and pressure to lower drug prices.
2. Amgen's lung cancer drug, Lumakras, did not receive traditional approval from the FDA, potentially limiting its market opportunity.

[Prediction & Analysis]:
Based on the positive developments such as the potential approval of Tarlatamab for small cell lung cancer treatment and Amgen's commitment to addressing climate change through its self-imposed carbon price, it is reasonable to expect a positive sentiment around the company. However, the concerns related to regulatory challenges and the limited approval of Lumakras may pose some downward pressure on the stock.

Considering the overall positive developments and the lack of significant negative news, it is likely that Amgen's stock price will experience a moderate increase of more than 5% in the upcoming week (2023-12-31 to 2024-01-07). Investors may be optimistic about the potential approval of Tarlatamab and the company's strategic response to climate change. However, it is essential to monitor any further developments related to regulatory challenges and the impact on drug pricing in the industry."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 165990.80 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-12-10 to 2023-12-17, AMGN's stock price increased from 269.12 to 275.45. Company news during this period are listed below:

[Headline]: No global carbon price? Some companies set their own
[Summary]: BOSTON/DUBAI/SAN FRANCISCO (Reuters) -A growing list of global companies are setting a price or charging themselves for each metric ton of their carbon emissions, looking to shape their investments and business for future pollution taxes or other new climate rules.  Their prices are all over the place, from less than $1 per metric ton of carbon emissions to $1,600, the most of any company worldwide, set by California drugmaker Amgen.  Regulators, too, have offered a range of prices, including the Biden administration's ""social cost"" of carbon, around $200, and a suggestion from the International Monetary Fund that it should be at least $85 by 2030.

[Headline]: Amgen raises dividend to $2.25 a share
[Summary]: Amgen Inc. said late Tuesday its board has authorized a dividend of $2.25 a share, up from $2.13 a share. That’s the 12th straight year that Amgen has...

[Headline]: AMGEN TO SPONSOR THE IRISH OPEN
[Summary]: Amgen (NASDAQ:AMGN) today announced it will serve as the title sponsor of the Irish Open starting in 2024, following the acquisition of Horizon Therapeutics plc in October 2023. Horizon Therapeutics, a leading Irish company, began sponsoring the tournament in 2022 as part of a multi-year commitment to the Irish community.

[Headline]: Amgen finds a new top scientist in Novartis veteran Bradner
[Summary]: Jay Bradner, a well-known physician-scientist who left Novartis last year amid an organizational shakeup, will now serve a Amgen’s chief scientific officer and head of R&D.

[Headline]: Dividend Champion, Contender, And Challenger Highlights: Week Of December 17
[Summary]: Weekly summary of dividend activity for Dividend Champions, Contenders, Challengers. Read more to see the companies with upcoming ex-dividend dates.

From 2023-12-17 to 2023-12-24, AMGN's stock price increased from 275.45 to 284.16. Company news during this period are listed below:

[Headline]: Dividend Champion, Contender, And Challenger Highlights: Week Of December 17
[Summary]: Weekly summary of dividend activity for Dividend Champions, Contenders, Challengers. Read more to see the companies with upcoming ex-dividend dates.

[Headline]: 7 Dividend Stocks to Buy as Bond Yields Fall
[Summary]: Stocks that pay growing dividends are starting look more attractive as bond yields have dropped.  The rate of inflation has continued to decline, and the Federal Reserve is now more likely to cut short-term interest rates than lift them.  Fatter yields from stock dividends now beckon.

[Headline]: Amgen shares rise as analysts see ‘value obesity play’
[Summary]: Shares of Amgen Inc. gained 1.1% premarket on Tuesday after BMO Capital Markets analysts upgraded the stock to outperform, from market perform, citing the...

[Headline]: Amgen Inc. (NASDAQ:AMGN) is largely controlled by institutional shareholders who own 78% of the company
[Summary]: Key Insights Given the large stake in the stock by institutions, Amgen's stock price might be vulnerable to their...

[Headline]: For Those Investors Stuck On Yield, 2023 Was Opportunistic
[Summary]: Discover the power of active stock picking and contrarian investing in today's volatile market. Click here to read what investors need to know.

From 2023-12-24 to 2023-12-31, AMGN's stock price increased from 284.16 to 288.02. Company news during this period are listed below:

[Headline]: UPDATE 2-US FDA turns down full approval of Amgen lung cancer drug Lumakras
[Summary]: The U.S. health regulator on Tuesday declined to grant traditional approval to Amgen's Lumakras for treating lung cancer patients with a specific gene mutation, although it kept the drug's existing accelerated approval status.  The U.S. Food and Drug Administration (FDA) now requires data from an additional confirmatory study to support the drug's full approval, which will be completed no later than February 2028, the company said.  Lumakras was approved by the FDA in 2021 under an accelerated pathway, with confirmatory data as a condition for gaining traditional approval.

[Headline]: FDA Rejects Amgen's (AMGN) NDA Seeking Full Nod for Lumakras
[Summary]: Per the FDA, Amgen (AMGN) will need to complete an additional confirmatory study on Lumakras in certain lung cancer patients before February 2028 to secure full approval.

[Headline]: Amgen Inc. stock outperforms market on strong trading day
[Summary]: Shares of Amgen Inc. inched 0.67% higher to $288.46 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...

[Headline]: Can Amgen's Price Strength Continue Into 2024?
[Summary]: Biotechnology firm Amgen  has moved higher on the charts the past seven months and made a new 52-week high on Thursday.  Can this price strength continue or are we looking at a ""last gasp"" as we head into the new year?  Prices are trading above the 50-day moving average line but the slope of the line is neutral or flat.

[Headline]: Amgen (AMGN) Stock Moves -0.15%: What You Should Know
[Summary]: The latest trading day saw Amgen (AMGN) settling at $288.02, representing a -0.15% change from its previous close.

From 2023-12-31 to 2024-01-07, AMGN's stock price increased from 288.02 to 303.00. Company news during this period are listed below:

[Headline]: Johnson & Johnson: Rock Solid 3% Yield With Over 10% Return Potential (Rating Upgrade)
[Summary]: Johnson & Johnson offers a safe and attractive investment opportunity with solid growth, a strong balance sheet, and a +3% dividend yield. Learn more on JNJ stock here.

[Headline]: Why the Market Dipped But Amgen (AMGN) Gained Today
[Summary]: Amgen (AMGN) reachead $303.17 at the closing of the latest trading day, reflecting a +0.82% change compared to its last close.

[Headline]: Generate : Biomedicines Fortifies Leadership in Generative AI with Advancing Clinical Pipeline and Expanded Amgen Collaboration, Overviewed at the 42nd Annual J.P. Morgan Healthcare Conference
[Summary]: Cambridge - Generate:Biomedicines today announced key advancements across its clinical pipeline and generative AI platform, including its first patient dosed in GB-0895, progress in the phase 1 study...

[Headline]: Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know
[Summary]: In the closing of the recent trading day, Amgen (AMGN) stood at $303, denoting a -0.06% change from the preceding trading day.

[Headline]: These Dow Stocks Will Boost Their Dividends Soon
[Summary]: In this article, we discuss 10 Dow stocks that will boost their dividends soon. You can skip our detailed analysis of dividend stocks and their performance over the years, and go directly to read These 5 Dow Stocks Will Boost Their Dividends Soon. The Dow Jones Industrial Average, known as the Dow, is a famous […]

[Basic Financials]:

No basic financial reported.

Based on all the information before 2024-01-07, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2024-01-07 to 2024-01-14) is up by 1-2%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen announced a dividend increase, which shows the company's commitment to rewarding shareholders and its confidence in its financial position.
2. Amgen has been making strategic moves, such as sponsoring the Irish Open and appointing a new top scientist, which can enhance its brand reputation and drive future growth.

[Potential Concerns]:
1. The U.S. FDA declined to grant full approval for Amgen's lung cancer drug, requiring additional confirmatory studies. This could impact the company's revenue and delay the drug's potential success.
2. The stock price is influenced by broader market trends, such as falling bond yields. Any negative market sentiments could impact Amgen's stock performance.

[Prediction & Analysis]:
Based on the positive developments, including the dividend increase and strategic moves, it indicates that Amgen is focused on value creation for shareholders. These factors could contribute to a positive sentiment around the company. However, the FDA's decision regarding the lung cancer drug could create uncertainty and potential downside risk.

Considering the positive developments and potential concerns, as well as the overall positive sentiments in the market, we predict that Amgen's stock price will increase by 1-2% in the upcoming week. Investors may view the dividend increase as a positive signal and be attracted to the company's strong brand reputation in the biotechnology sector. However, it is essential to monitor any developments related to the FDA's decision, as it could impact the stock price in the short term."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 165990.80 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-12-24 to 2023-12-31, AMGN's stock price increased from 284.16 to 288.02. Company news during this period are listed below:

[Headline]: UPDATE 2-US FDA turns down full approval of Amgen lung cancer drug Lumakras
[Summary]: The U.S. health regulator on Tuesday declined to grant traditional approval to Amgen's Lumakras for treating lung cancer patients with a specific gene mutation, although it kept the drug's existing accelerated approval status.  The U.S. Food and Drug Administration (FDA) now requires data from an additional confirmatory study to support the drug's full approval, which will be completed no later than February 2028, the company said.  Lumakras was approved by the FDA in 2021 under an accelerated pathway, with confirmatory data as a condition for gaining traditional approval.

[Headline]: Amgen Inc. stock underperforms Tuesday when compared to competitors
[Summary]: Shares of Amgen Inc. dropped 0.09% to $283.90 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...

[Headline]: TScan: Two 2024 TCR-T Data Readouts Could Bring Significant Value
[Summary]: TScan's results from T-Plex targeting patients with solid tumors in the Phase 1 study are expected to be released in 2024. Read my analysis of TCRX stock.

[Headline]: Amgen Inc. stock falls Friday, still outperforms market
[Summary]: Shares of Amgen Inc. sank 0.15% to $288.02 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...

[Headline]: Chevron, Kimberly-Clark Among 14 Companies To Announce Dividend Increases In January
[Summary]: Investors celebrate double-digit increases for Mastercard and Broadcom.

From 2023-12-31 to 2024-01-07, AMGN's stock price increased from 288.02 to 303.00. Company news during this period are listed below:

[Headline]: Chevron, Kimberly-Clark Among 14 Companies To Announce Dividend Increases In January
[Summary]: Investors celebrate double-digit increases for Mastercard and Broadcom.

[Headline]: Dow Dogs Gain Some Respect In Q4 2023
[Summary]: In the fourth quarter, the Dow Dogs generated mid-teens growth that resulted in the 2023 total return equaling 14.5% for the year and almost matching the Dow's return of 16.0%.

[Headline]: AMGEN TO PRESENT AT THE 42ND ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
[Summary]: Amgen (NASDAQ:AMGN) will present at the 2024 J.P. Morgan Healthcare Conference at 9:00 a.m. PT on Monday, January 8, 2024. Robert A. Bradway, chairman and chief executive officer at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

[Headline]: How The Supreme Court's Decision In Amgen v. Sanofi Impacts Pharmaceutical Patents
[Summary]: On May 18, 2023, the Supreme Court of the United States handed down its decision in Amgen Inc. v. Sanofi 1 , a fairly notorious case among pharmaceutical companies and patent nerds. Amgen/Sanofi is...

[Headline]: Johnson & Johnson's Bullish Outlook: Surprising Strength You Shouldn't Overlook
[Summary]: Johnson & Johnson is a Dividend King focused on the creation and manufacturing of medical devices, vaccines, and medicines. Read more about JNJ stock here.

From 2024-01-07 to 2024-01-14, AMGN's stock price increased from 303.00 to 306.51. Company news during this period are listed below:

[Headline]: Dow Jones Leader Amgen Extends Gains Past Buy Point; Ozempic Maker Novo Nordisk Breaks Out
[Summary]: Dow Jones biotech leader Amgen extended its breakout gains, while Ozempic maker Novo Nordisk is in buy range past its latest buy point.

[Headline]: Dow Jones Futures: Magnificent Seven Stocks Rally; Nvidia Breaks Out Past Buy Point
[Summary]: Dow Jones futures: The Magnificent Seven stocks rallied sharply Monday, with Nvidia stock breaking out past a new buy point to record highs.

[Headline]: JPM's annual healthcare conference: Here's what's next for GLP-1s and the weight loss market
[Summary]: Several big pharma companies are rushing into the GLP-1 obesity space, which currently has two market leaders. How they plan to take some of that market share will be the story of the drug class for 2024.

[Headline]: Amgen Inc. stock outperforms competitors on strong trading day
[Summary]: Shares of Amgen Inc. rose 1.13% to $306.51 Friday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index...

[Headline]: Vectoring In On Verve Therapeutics
[Summary]: Verve's lead candidate, VERVE-101, has shown promising results in reducing LDL-C levels in preclinical studies. Find out my recommendation on VERV stock.

[Basic Financials]:

No basic financial reported.

Based on all the information before 2024-01-14, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2024-01-14 to 2024-01-21) is up by 0-1%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen's drug, Lumakras, maintained its accelerated approval status for treating lung cancer patients with a specific gene mutation, indicating its efficacy in the market.
2. Amgen's stock price showed consistent growth during the analyzed period, outperforming competitors and the overall market on multiple occasions.

[Potential Concerns]:
1. The FDA's decision to require additional data for Lumakras' full approval may introduce delays in the regulatory process, potentially affecting the drug's market penetration and revenue growth.
2. The mixed trading session for the stock market during the analyzed period could indicate potential volatility and uncertainty that could impact Amgen's stock price.

[Prediction & Analysis]:
Based on the positive developments, such as the maintenance of Lumakras' accelerated approval status and Amgen's consistent stock price growth, it is reasonable to expect a continuation of these positive trends in the upcoming week. The market's recognition of Amgen as a leader in the biotech sector, along with potential positive news from the J.P. Morgan Healthcare Conference, where Amgen's CEO is scheduled to present, could further boost investor confidence and drive the stock price higher. Considering these factors, a prediction of a 0-1% increase in Amgen's stock price for the next week seems plausible."
